Document:

Settlement Agreement & Releases

 Exhibit 10.1 
 WHENEVER CONFIDENTIAL INFORMATION IS OMITTED HEREIN (SUCH OMISSIONS ARE DENOTED BY AN ASTERISK *), SUCH CONFIDETNAIL INFORMATION HAS BEEN SUBMITTED SEPARATE TO THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT. 
 SETTLEMENT AGREEMENT AND RELEASES 
 This Settlement Agreement and Releases (the “Settlement Agreement”) is made and entered into by and among Massachusetts Institute of Technology
(“MIT”), Repligen Corporation (“Repligen”) and ImClone Systems Incorporated (“ImClone”) (MIT, Repligen and ImClone are referred to herein individually as a “Party” and collectively as the “Parties”).

 WHEREAS, MIT and Repligen are the Plaintiffs-Counter Defendants and ImClone is the Defendant-Counter Claimant in the action entitled
Massachusetts Institute of Technology and Repligen Corporation v. ImClone Systems, Inc., Civil Action No. 04 cv 10884 (RGS), pending in the United States District Court for the District of Massachusetts (the “Action”); and

 WHEREAS, the Parties desire to settle the Action on the terms stated herein, without any admission of liability or wrongdoing, and in
order to avoid the time and expense of continuing to litigate the Action; 
 NOW, THEREFORE, in consideration of the mutual covenants and
agreements contained herein, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, and intending to be bound hereby, the Parties hereby agree as follows: 
 1. ImClone Payment to MIT and Repligen. ImClone shall pay to MIT and Repligen by wire transfer to their attorneys Fish & Richardson P.C.
to the account below $65,000,000.00 (sixty-five million dollars and zero cents) for the releases and sublicenses contained herein, which wire transfer shall be initiated within three business days of the Effective Date (as defined in Paragraph 21
below). 
  

 * – Confidential Treatment Requested 

			
	 Bank Name:
  
             Bank of America
             100 Federal Street
             Boston, MA 02110
	  	 Name on Acct:
  
             Fish & Richardson P.C.
             Massachusetts IOLTA Committee Acct No. [*]
             ABA No. 0260-0959-3
             Swift Code: BOFAUS3N

 2. Definitions. 
 a. “Affiliate” means any individual, corporation, partnership, proprietorship or other entity controlled by, controlling, or under common
control with a Party to this Agreement through, directly or indirectly, equity ownership, ability to elect directors, or by virtue of a majority of overlapping directors, or by contract, or otherwise, and shall include, but shall not be limited to
that instance where any individual, corporation, partnership, proprietorship or other entity directly or indirectly owning, owned by or under common ownership with the party in question to the extent of fifty percent (50%) or more of the equity
of voting shares, including shares owned beneficially by such Party. 
 b. “Excluded Fields” means any application or use [*].

 c. “TLA” means Technology Licensing Agreement between Abbott Biotech, Inc. and Repligen Corporation, dated May 14, 1992,
attached hereto as Exhibit A. 
 3. Patent Sublicenses. 
 a. MIT and Repligen agree that Repligen shall grant ImClone and its Affiliates a sublicense under United States Patent No. 4,663,281 (the “‘281 Patent”), together with any continuations,
continuations-in-part, divisions, foreign counterparts and equivalents thereto, in the form attached hereto as Exhibit B executed simultaneously with and as a condition of this Settlement Agreement. 
  
 * – Confidential Treatment Requested 
  

 2 

 b. Consistent with the rights granted Repligen under the TLA, Repligen shall grant ImClone and its
Affiliates a sublicense under United States Patent No. 5,665,578 (the “‘578 Patent”) and United States Patent No. 5,741,682 (the “‘682 Patent”), together with any continuations, continuations-in-part,
divisions, foreign counter-parts and equivalents thereto, under which and solely to the extent that Repligen has the power to grant rights under the TLA, in the form attached hereto as Exhibit C executed simultaneously with and as a condition of
this Settlement Agreement. 
 4. General Releases. 
 a. Effective immediately after receipt into the transferee account of the funds subject to the wire payment referred to in Paragraph 1 above, Repligen, on behalf of itself and its agents, servants, attorneys,
employees, officers, directors, members, shareholders, subsidiaries, parents, Affiliates, predecessors, successors, assigns, transferees, representatives and all persons and entities acting by, through, under, or in concert with them or any of them
(the “Repligen Releasors”) fully and forever release and discharge ImClone and each of ImClone’s current and former agents, servants, attorneys, employees, officers, directors, members, shareholders, subsidiaries, parents, Affiliates,
predecessors, successors, assigns, transferees, representatives and all persons and entities acting by, through, under, or in concert with them or any of them (the “ImClone Released Parties”) from any and all manner of action or actions,
in law or in equity, for indemnity or otherwise, claims, counterclaims, demands, cause or causes of action, suits, debts, liens, damages, losses, costs or expenses, liabilities of any kind, fees, commissions and other payments whether presently
known or unknown, accrued or not accrued, foreseen or not foreseen, matured or not matured, asserted or unasserted, fixed or contingent, which any of the Repligen Releasors may have had, may claim to have had, ever had, may have, may claim to have
or now have against the ImClone Released Parties from the beginning of time until the 
  
 * – Confidential Treatment Requested 
  

 3 

 
Effective Date, in connection with the making, use or sale of C225 (i.e., Erbitux®) and/or in connection with the making, use, or sale of IMC-11F8,
including without limitation all claims for infringement of the ‘281 Patent or any other existing patent together with any continuations, continuations-in-part, divisions, foreign counterparts and equivalents thereto. 
 b. Effective immediately after receipt into the transferee account of the funds subject to the wire payment referred to in Paragraph 1 above, MIT on
behalf of itself and its agents, servants, attorneys, employees, officers, directors, members, shareholders, subsidiaries, parents, Affiliates, predecessors, successors, assigns, transferees, representatives and all persons and entities acting by,
through, under, or in concert with them or any of them (the “MIT Releasors”) fully and forever release and discharge ImClone and each of ImClone’s current and former agents, servants, attorneys, employees, officers, directors,
members, shareholders, subsidiaries, parents, Affiliates, predecessors, successors, assigns, transferees, representatives and all persons and entities acting by, through, under, or in concert with them or any of them (the “ImClone Released
Parties”) from any and all manner of action or actions, in law or in equity, for indemnity or otherwise, claims, counterclaims, demands, cause or causes of action, suits, debts, liens, damages, losses, costs or expenses, liabilities of any
kind, fees, commissions and other payments whether presently known or unknown, accrued or not accrued, foreseen or not foreseen, matured or not matured, asserted or unasserted, fixed or contingent, which any of the MIT Releasors may have had, may
claim to have had, ever had, may have, may claim to have or now have against the ImClone Released Parties from the beginning of time until the Effective Date, in connection with the making, use or sale of C225 (i.e., Erbitux), on all claims for
infringement of the ‘281 Patent (including claims for future damages or injunctive relief related thereto), together with any continuations, continuations-in-part, divisions, foreign counterparts and equivalents thereto of the ‘281 patent.

  
 * – Confidential Treatment Requested 
  

 4 

 c. Effective immediately after receipt into the transferee account of the funds subject to the wire
payment referred to in Paragraph 1 above, ImClone, on behalf of itself and its agents, servants, attorneys, employees, officers, directors, members, shareholders, subsidiaries, parents, Affiliates, predecessors, successors, assigns, transferees,
representatives and all persons and entities acting by, through, under, or in concert with them or any of them (the “ImClone Releasors”) fully and forever release and discharge Repligen and its current and former respective agents,
servants, attorneys, employees, officers, directors, members, shareholders, subsidiaries, parents, Affiliates, predecessors, successors, assigns, transferees, representatives and all persons and entities acting by, through, under, or in concert with
them or any of them (the “Repligen Released Parties”) from any and all manner of action or actions, in law or in equity, for indemnity or otherwise, claims, counterclaims, demands, cause or causes of action, suits, debts, liens, damages,
losses, costs or expenses, liabilities of any kind, fees, commissions and other payments whether presently known or unknown, accrued or not accrued, foreseen or not foreseen, matured or not matured, asserted or unasserted, fixed or contingent, which
any of the ImClone Releasors may have had, may claim to have had, ever had, may have, may claim to have or now have against the Repligen Released Parties from the beginning of time until the Effective Date, in connection with the making, use or sale
of C225 (i.e., Erbitux) and/or in connection with the making, use, or sale of IMC-11F8, including without limitation all counterclaims with regard to the ‘281 Patent or any other existing patent together with any continuations,
continuations-in-part, divisions, foreign counterparts and equivalents thereto. 
 d. Effective immediately after receipt into the transferee
account of the funds subject to the wire payment referred to in Paragraph 1 above, ImClone Releasors fully and forever release and discharge MIT and its current and former respective agents, servants, attorneys, employees, officers, directors,
members, shareholders, subsidiaries, parents, Affiliates, 
  
 * – Confidential Treatment Requested 
  

 5 

 
predecessors, successors, assigns, transferees, representatives and all persons and entities acting by, through, under, or in concert with them or any of
them (the “MIT Released Parties” from any and all manner of action or actions, in law or in equity, for indemnity or otherwise, claims, counterclaims, demands, cause or causes of action, suits, debts, liens, damages, losses, costs or
expenses, liabilities of any kind, fees, commissions and other payments whether presently known or unknown, accrued or not accrued, foreseen or not foreseen, matured or not matured, asserted or unasserted, fixed or contingent, which any of the
ImClone Releasors may have had, may claim to have had, ever had, may have, may claim to have or now have against the MIT Released Parties from the beginning of time until the Effective Date, in connection with the making, use or sale of C225 (i.e.,
Erbitux), on all counterclaims with regard to the ‘281 Patent (including claims for future damages or injunctive relief related thereto), together with any continuations, continuations-in-part, divisions, foreign counterparts and equivalents
thereto of the ‘281 patent. 
 5. ImClone Purchase of Protein A Resins. To fulfill ImClone’s need for Protein A for
ImClone’s manufacture of C225 (i.e., Erbitux), ImClone hereby agrees to continue to purchase until expiration of the latest to expire of the patents being sublicensed pursuant to this Settlement Agreement, in accordance with past business
practices, resins made with recombinant Protein A (including recombinant mutants and derivatives of Protein A) manufactured for or by Repligen, its Affiliates, or a third party that acquires, whether by sale, merger, recapitalization, or other
business combination, all or substantially all of the assets of Repligen or Repligen’s Protein A business for ImClone’s manufacturing of C225 (i.e., Erbitux), provided that such resins are sold (i) at fair market price, (ii) with
a quality level reasonably acceptable to ImClone. If there comes a time when available resins made with recombinant Protein A manufactured for or by Repligen do not satisfy ImClone’s demand for resins for manufacturing C225 (i.e., Erbitux) then
ImClone’s obligation to purchase under this Paragraph 5 shall immediately cease. [*] 
  
 * – Confidential Treatment Requested 
  

 6 

 6. Attorneys’ Fees and Costs. The Parties shall bear their own respective attorneys’
fees and costs. 
 7. No Admission of Wrongdoing. The Parties expressly acknowledge that this Settlement Agreement represents a
settlement of disputed rights and claims. Nothing in the terms of this Settlement Agreement or in its execution shall be construed as an admission of liability or wrongdoing as to any matter by the Parties hereto. ImClone affirmatively denies the
allegations contained in the Complaint in the Action, and MIT and Repligen affirmatively deny the allegations contained in the Counterclaims in the Action. 
 8. Dismissal with Prejudice. The Parties shall execute at the time this Settlement Agreement is executed a stipulation dismissing with prejudice the Complaint and Counterclaims in the Action in the form
attached hereto as Exhibit D, which shall be held in escrow by counsel for MIT and Repligen and submitted to the Court for filing within one business day after receipt into the transferee account of the funds subject to the wire transfer payment
referred to in Paragraph 1 above. The stipulation of dismissal shall provide that the Parties shall bear their own respective attorneys’ fees and costs. 
 9. Confidentiality. The Parties shall keep the terms of this Settlement Agreement confidential, except that (i) any Party may disclose that the Action has been resolved by settlement with no Party
admitting liability, (ii) any Party may disclose the terms of this Settlement Agreement as required by the securities laws, (iii) any Party may disclose the terms of this Settlement Agreement as otherwise required by law, and
(iv) ImClone may disclose the terms of this Settlement Agreement (including without limitation the terms of the sublicenses referred to in Paragraph 3 above) to any collaboration partner or manufacturing partner of ImClone provided such
disclosure is made under obligations of confidentiality between ImClone and such partners pursuant to the agreement(s) they have entered into. Notwithstanding the 
  
 * – Confidential Treatment Requested 
  

 7 

 
foregoing, any Party may disclose the terms of this Settlement Agreement in any proceeding to enforce the terms of this Settlement Agreement. To the extent
any Party is required to disclose information about this settlement pursuant to Subparagraph (iii) above in order to comply with a subpoena, document request or order issued by a court of competent jurisdiction or by a state or federal
regulatory body, the Party receiving such subpoena or order, upon receipt thereof, shall promptly notify the other Parties of the existence, terms and circumstances surrounding such subpoena, document request or order prior to disclosure of the
information. If disclosure is to be made pursuant to Subparagraph (iii) above, the disclosing Party shall exercise its best efforts to cooperate with any other Party that seeks a protective order. Notwithstanding the foregoing provisions of
this Paragraph 9, the Parties may publish press releases concerning this Settlement Agreement in the mutually agreeable forms attached hereto as Exhibit E and Exhibit F and may make any public disclosures that are consistent with the disclosures
contained in the press release and the Parties’ prior periodic disclosures. 
 10. Representations, Warranties and Covenants of the
Parties. The Parties hereby represent, warrant and agree as follows: 
 a. MIT and Repligen each represents and warrants that Repligen has
the full right, power, and authority to grant the sublicense referred to in Paragraph 3(a) of this Settlement Agreement. EXCEPT AS EXPRESSLY SET FORTH HEREIN, MIT AND REPLIGEN MAKE NO EXPRESS OR IMPLIED WARRANTIES AND DISCLAIM ALL IMPLIED
WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, AND AGAINST INFRINGEMENT. 
 b. As of the Effective Date, consistent with the rights and restrictions to which Repligen is subject to under the TLA, Repligen represents and warrants to ImClone that 
  
 * – Confidential Treatment Requested 
  

 8 

 
Repligen has the full right, power and authority to enter into this Settlement Agreement, and to grant the sublicense granted in Paragraph 3(b) hereof.
EXCEPT AS EXPRESSLY SET FORTH HEREIN, REPLIGEN MAKES NO EXPRESS OR IMPLIED WARRANTIES AND DISCLAIMS ALL IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, AND AGAINST
INFRINGEMENT. 
 c. Repligen represents and warrants that (i) to the best of Repligen’s knowledge and belief, Repligen has provided
ImClone with a complete and accurate copy of the TLA in effect as of the Effective Date, (ii) to the best of Repligen’s knowledge and belief, the TLA is in full force and effect as of the Effective Date, (iii) to the best of
Repligen’s knowledge and belief, no party to the TLA is in material breach of the TLA as of the Effective Date and Repligen is not aware of any circumstance which would give rise to material breach of the TLA as of the Effective Date,
(iv) no party to the TLA has notified in writing any other party to the TLA of any material breach of the TLA that remains uncured as of the Effective Date, and (v) Repligen has not voluntarily terminated the TLA pursuant to paragraph 6(b)
of the TLA or otherwise terminated the TLA by mutual agreement with Abbott. 
 d. Repligen hereby covenants and agrees that: 
 (i) to the extent it is within Repligen’s control (a) it will maintain and not terminate, invalidate, encumber or diminish the TLA and/or the
patents sublicensed thereunder, and (b) it will not modify or amend (or consent to modification or amendment of) the TLA, in each case only insofar as it affects the rights and obligations of Repligen thereunder with respect to rights and
obligations of ImClone under this Agreement, without the written permission of ImClone; and 
  
 * – Confidential Treatment Requested 
  

 9 

 (ii) any assignment of the TLA by Repligen is subject to this Agreement and ImClone shall be promptly
provided with written notice of such assignment; and 
 (iii) it will promptly provide ImClone with any notice of material breach of the TLA
and/or intent to terminate the TLA and/or the rights and sublicenses thereunder, to the extent Repligen is aware of the foregoing, and it shall use commercially reasonable efforts to attempt to cure any such breach and/or to prevent termination of
such TLA and/or such rights and licenses thereunder, except to the extent caused by ImClone or its Affiliates; and if Repligen fails to promptly do so, ImClone shall have the right, but not the obligation, to cure such breach and/or prevent such
termination. 
 e. ImClone represents and warrants that it and its Affiliates have the full right and authority to accept and be bound by the
conditions and restrictions of the TLA applicable to sublicensees. ImClone further represents and warrants that it and its Affiliates are not engaged, and have no current intent to engage in the future, in any research, development,
commercialization or other activity in any of the areas of [*]. EXCEPT AS EXPRESSLY SET FORTH HEREIN, IMCLONE MAKES NO EXPRESS OR IMPLIED WARRANTIES AND DISCLAIMS ALL IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY IMPLIED WARRANTIES OF
MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, AND AGAINST INFRINGEMENT. 
 f. With the exception of the claim asserted in the Action,
MIT and Repligen each represents and warrants that it has no claims against ImClone relating to the ‘281 patent. Repligen represents and warrants that as of the Effective Date it has no knowledge of any claim against ImClone. 
 g. The persons executing this Settlement Agreement on behalf of MIT, Repligen and ImClone, respectively, represent and warrant that they each are
authorized and 
  
 * – Confidential Treatment Requested 

 

 10 

 
have capacity to sign for and bind the respective entities for which they sign. Each of the Parties shall be responsible for any breach of this
representation and warranty by its respective signatory hereto, and such signatory shall not incur any personal liability by virtue of any breach of this representation and warranty. 
 h. Each Party represents and warrants that it has not sold, assigned, transferred, conveyed or otherwise disposed of any right, title or interest to any
claim that is released by the Settlement Agreement. 
 i. Each Party represents and warrants that it has relied upon its own judgment and
that of its own legal counsel regarding the proper, complete, and agreed-upon consideration for, and the terms and provisions of, this Settlement Agreement, the sublicenses referred to in Paragraph 3 above and the stipulation of dismissal to be
executed simultaneously herewith, and that no Party has relied on any representation or warranty (express or implied) made by any other Party or any of its agents, employees or legal counsel, other than as expressly set forth in this Settlement
Agreement, in entering into this Settlement Agreement. 
 11. Further Assurances. Each Party shall execute and deliver to the others
such additional documents and take such other actions as may be reasonably requested by any other Party in order to carry out the terms and conditions of this Settlement Agreement. 
 12. Successors and Third Parties. This Settlement Agreement is binding upon, and shall inure to the benefit of, the Parties and their respective
affiliates, subsidiaries and each of their employees, officers, directors, agents, successors and assigns. 
 13. Merger and
Integration. This Settlement Agreement, along with the sublicenses referred to in Paragraph 3 above and the stipulation of dismissal executed simultaneously herewith, constitutes the entire, complete and integrated agreement made between the
Parties regarding the subject matter hereof. The Settlement Agreement is not subject to any conditions 
  
 * – Confidential Treatment Requested 
  

 11 

 
not expressly provided for herein, and this Settlement Agreement, along with the TLA, sublicenses, stipulation of dismissal and press release, cancel and
supercede all earlier agreements, written or oral, between the parties regarding the subject matter hereof. 
 14. Headings. All
headings used in this Settlement Agreement are intended for ready reference and convenience only. The headings must not be given any force and are without contractual significance or effect. 
 15. Amendments. This Settlement Agreement may not be modified, altered, amended, waived or changed in any way, except in a writing signed by the
Parties. 
 16. Waiver. A failure by any Party to enforce any provision of this Settlement Agreement or a right under this Settlement
Agreement may not be construed as: 
 a. A waiver of any right; 
 b. Having any effect on the validity of this Settlement Agreement or any part thereof; or 
 c. A prejudice
for or against any Party in a subsequent legal action. 
 Any Party may waive any of its rights under this Settlement Agreement only by an appropriate
writing that specifically refers to the contractual right that is being waived and that is signed by the waiving Party. 
 17.
Construction. Neither this Settlement Agreement nor any provision in this Settlement Agreement shall be construed for or against any Party because the Settlement Agreement as a whole, or any provision of this Settlement Agreement, was
requested or drafted by such Party. Neither this Settlement Agreement nor any provision in this Settlement Agreement nor evidence of any negotiations in connection with it or them shall be offered or received in evidence or used in any way in any
action or proceeding between the Parties except to enforce the terms and provisions hereof. 
  
 * – Confidential Treatment Requested 
  

 12 

 18. Controlling Law, Jurisdiction and Venue. This Settlement Agreement shall be governed by and
construed in accordance with the laws of the Commonwealth of Massachusetts without regard to its principles of choice of law. The Parties agree to request that the United States District Court for the District of Massachusetts retain jurisdiction of
the Action for purposes of enforcement of this Settlement Agreement. Each Party irrevocably submits to the exclusive jurisdiction of (i) Courts of the Commonwealth of Massachusetts, Suffolk County, and (ii) the United States District Court
for the District of Massachusetts, for the purposes of any suit, action or other proceeding arising out of this Settlement Agreement and waives any defense or objection based on lack of personal jurisdiction. Each Party agrees to commence any such
action, suit or other proceeding in the United States District Court for the District of Massachusetts, or, in the event such suit, action or other proceeding may not be brought in such court for jurisdictional reasons, in the Courts of the
Commonwealth of Massachusetts, Suffolk County. Each Party further agrees that service of any process, summons, notice or document by certified mail, return receipt requested, to such Party’s respective address set forth below shall be effective
service of process for any action, suit or other proceeding in the Commonwealth of Massachusetts with respect to any matters to which it has submitted to jurisdiction in this Paragraph. Each Party irrevocably and unconditionally waives any defense
or objection to the laying of venue of any action, suit or other proceeding arising out of this Settlement Agreement in (i) Courts of the Commonwealth of Massachusetts, Suffolk County, or (ii) the United States District Court for the
District of Massachusetts, and hereby and thereby further irrevocably and unconditionally waives and agrees not to plead or claim any defense or objection in any such court that any such action, suit or other proceeding brought in any such court has
been brought in an inconvenient forum. 
  
 * – Confidential
Treatment Requested 
  

 13 

 a. All notices and other communications to MIT must be sent to: 
 Massachusetts Institute of Technology 
 77
Massachusetts Avenue 
 NE 25-230 
 Cambridge, MA 02139 
 Attention: Director, Technology Licensing Office 
 b. All notices and other communication to Repligen must be sent to: 
 Repligen Corporation 
 41 Seyon Street 
 Building #1, Suite 100 
 Waltham, MA 02453 
 Attention: President and Chief Executive Officer 
 c. All notices and other communications to ImClone must be sent to: 
 ImClone Systems Incorporated 
 180 Varick Street 
 New York, NY 10014

 Attention: General Counsel 
 19. Notices. All notices and other communications required or permitted to be sent under this Settlement Agreement must be in writing. Except for those notices and communications governed by Paragraph 18 above, and unless otherwise
agreed, all notices must be sent by: 
 a. Certified mail, return receipt requested; or 
 b. Facsimile with a confirmation copy dispatched contemporaneously either by certified mail, return receipt requested, or by courier service. 

All notices and other communications to MIT must be sent to the address listed in Paragraph 18(a) above, all notices and other communications to Repligen must be sent
to the address listed in Paragraph 18(b) above, and all notices and other communications to ImClone must be sent to the address listed in Paragraph 18(c) above. 
 20. Counterparts. This Settlement Agreement may be executed in any number of counterparts, each of which shall be deemed to be one and the same instrument. 
  
 * – Confidential Treatment Requested 
  

 14 

 21. Effective Date. This Settlement Agreement is effective as of the date it has been executed by
all the Parties (the “Effective Date”). 
 IN WITNESS WHEREOF, the Parties have caused this Settlement Agreement to be executed by
their duly authorized representatives in a manner legally binding upon their respective corporations as of the Effective Date. 
  

											
	REPLIGEN CORPORATION	 		 	IMCLONE SYSTEMS INCORPORATED
			
	Date: September 10, 2007	 		 	Date: September 10, 2007
				
	 /s/ Walter Herlihy
	 		 		 	 /s/ Daniel J. O’Connor

	By:	 	Walter C. Herlihy, Ph.D.	 		 		 	By:	 	Daniel J. O’Connor
		 	President and	 		 		 		 	General Counsel
		 	Chief Executive Officer	 		 		 		 	Senior Vice President
		 		 		 		 		 	General Counsel and Secretary

  

			
	MASSACHUSETTS INSTITUTE OF TECHNOLOGY
	
	Date: September 10, 2007
	
	 /s/ Lita Nelsen

	By:	 	Lita L. Nelsen
		 	Director, Technology Licensing Office

  
 * – Confidential
Treatment Requested 
  

 15 

					
	STATE OF MASSACHUSETTS    	 	)	  	
		 	:	  	        s.s.:
	COUNTY OF SUFFOLK                 	 	)	  	

 On this 10th day of September 2007, before me personally came Lita L. Nelsen, to me known, who, by me duly sworn, did depose and state that deponent is a Director, Technology Licensing Office
for the Massachusetts Institute of Technology, the corporation described in, and which executed, the foregoing SETTLEMENT AGREEMENT AND MUTUAL RELEASE. 
  

	
	 /s/ K.A. Murphy

	Notary Public

  

					
	STATE OF MASSACHUSETTS    	 	)	  	
		 	:	  	        s.s.:
	COUNTY OF SUFFOLK                 	 	)	  	

 On this 10th day of September 2007, before me personally came Walter C. Herlihy, Ph.D., to me
known, who, by me duly sworn, did depose and state that deponent is the President and Chief Executive Officer for Repligen Corporation, the corporation described in, and which executed, the foregoing SETTLEMENT AGREEMENT AND MUTUAL RELEASE.

  

	
	 /s/ K.A. Murphy

	 Notary Public

  

					
	STATE OF MASSACHUSETTS    	 	)	  	
		 	:	  	        s.s.:
	COUNTY OF SUFFOLK                	 	)	  	

 On this 10th day of September 2007, before me personally came Daniel J. O’Connor, to me
known, who, by me duly sworn, did depose and state that deponent is a Senior Vice President, General Counsel and Secretary of ImClone Systems Incorporated, the corporation described in, and which executed, the foregoing SETTLEMENT AGREEMENT AND
MUTUAL RELEASE. 
  

	
	 /s/ K.A. Murphy

	 Notary Public

  

 * – Confidential Treatment Requested 

 Exhibit A 
 TECHNOLOGY LICENSE AGREEMENT 
 BETWEEN ABBOTT BIOTECH, INC. 
 AND 
 REPLIGEN CORPORATION

 THIS AGREEMENT is made and entered into this 14 day of May, 1992, by and between ABBOTT BIOTECH, INC. (“LICENSOR”), and
REPLIGEN CORPORATION (“LICENSEE”). 
 This Agreement is entered into in connection with the acquisition by LICENSEE of certain
business, assets and obligations of LICENSOR pursuant to that certain Asset Purchase Agreement (“Purchase Agreement”) entered into among LICENSOR, LICENSEE and Abbott Laboratories, an Illinois corporation, contemporaneously herewith.
Pursuant to the Purchase Agreement, LICENSEE is acquiring, among other things, certain technology which is not the subject of this Agreement. By this Agreement, LICENSOR is granting to LICENSEE a non-exclusive license under certain Patent Rights (as
defined below) and a non-exclusive sublicense under certain licenses. 
 In consideration of the foregoing premises and the covenants and
conditions herein contained, the parties hereto agree as follows: 
 1. Definitions. 
 (a) “Patent Rights” shall mean all United States patents and patent applications listed in Exhibit A attached hereto and made a part hereof, and
all corresponding foreign patents and patent applications, including any and all divisions, continuations, continuations-in-part, reissues, and extensions thereof that exist now or that come into existence in the future, and relevant information and
documentation contained in the patent file history. 
 (b) “Licensed Product” shall mean any product, composition of matter, system
or apparatus which, but for this Agreement, would otherwise infringe a valid claim of an unexpired patent included in the Patent Rights. 
 (c) “Licensed Processes” shall mean any process, method, or method of use which, but for this Agreement, would otherwise infringe a valid claim of an unexpired patent in the Patent Rights. 
 (d) “Licensed Field” shall mean any application or use with the exception of the application or use [*]. 
 2. License and Sublicense. 
 (a)
LICENSOR hereby grants LICENSEE, to the extent of the Licensed Field, a worldwide, non-exclusive, royalty-free, fully paid-up license under the Patent Rights to make, have made, use and sell Licensed Product and to practice, have practiced, use and
sell Licensed Processes. 
  

 * – Confidential Treatment Requested 

 (b) LICENSOR hereby grants LICENSEE a non-exclusive sublicense in the Licensed Field under those rights
granted, and subject to all terms and conditions set forth, in the license agreement with the Massachusetts Institute of Technology (“M.I.T.”) attached hereto and made a part hereof as Exhibit B (the “M.I.T. License”) and the
license agreement with [*] (“[*]”) attached hereto and made a part hereof as Exhibit C (the “[*] License”). 
 3.
LICENSOR’s Obligations. LICENSOR shall have the sole right, but not the obligation, to prosecute, maintain and/or enforce the Patent Rights and any similar patent rights under the M.I.T. License and the [*] License. LICENSOR shall have
no obligation to maintain the M.I.T. License or the [*] License in force, and shall have no other obligation with respect to the Patent Rights, the M.I.T. License or the [*] License; provided, that in the event LICENSOR intends to terminate or let
lapse either the M.I.T. License or the [*] License, LICENSOR shall provide LICENSEE with at least sixty (60) days’ notice thereof and, at the written request of LICENSEE, shall assign to LICENSEE all of LICENSOR’s rights (subject to
all of its obligations) under either such agreement. Each of M.I.T. and [*] hereby consent to the assignment to LICENSEE under this Section 3 of either the M.I.T. License or the [*] License, as the case may be. LICENSOR shall have no
responsibility or liability for any acts, omissions or breaches of LICENSEE under this Agreement, the M.I.T. License, the [*] License or otherwise. Failure of LICENSEE to comply with the terms and conditions of the M.I.T. License or the [*] License
shall not be deemed a breach by LICENSOR under such license. 
 4. No Payments Except for Pass-Through. The license and sublicenses
hereunder are granted free of any license or sublicense fees, royalties or other payment obligations, except that LICENSEE shall be obligated to pay any royalties or other sums due to M.I.T. under the M.I.T. License or [*] under the [*] License as a
result of LICENSEE’s activities. 
 5. Compliance with M.I.T. License and [*] License. 
 (a) As a sublicensee under the M.I.T. License and the [*] License, LICENSEE shall comply with all terms and conditions of such licenses to the extent
applicable to its activities as though LICENSEE were the direct licensee under such licenses. LICENSEE shall provide to LICENSOR copies of any and all reports provided to M.I.T. or [*] under such licenses. 
 (b) LICENSEE shall keep accurate records in sufficient detail to enable payments due M.I.T. or [*] to be determined, in accordance with generally
accepted accounting principles. Upon LICENSOR’s written request and at LICENSOR’s expense, LICENSEE shall permit an independent certified public accountant selected and retained by LICENSOR and reasonably acceptable to LICENSEE to have
access, during regular business hours and upon reasonable notice to LICENSEE, to such records as may be necessary to verify the accuracy of the aforementioned reports and payments. 
 (c) To the extent that LICENSOR is required to do so pursuant to the terms of the relevant agreement or applicable law, LICENSEE shall be responsible for
deducting, and paying to appropriate fiscal or tax authorities on M.I.T.’s and [*]’s behalf and for LICENSEE’s account, all taxes assessed or imposed against, or required to be withheld from, payments due M.I.T. or [*], respectively,
as a result of LICENSEE’s activities. The amount of any such taxes paid or so withheld by LICENSEE shall be deducted from the royalties otherwise due to M.I.T. or [*], as the case may be. 
  

 * – Confidential Treatment Requested 

 (d) LICENSEE shall indemnify and hold LICENSOR harmless against all liabilities, damages, losses, costs
and expenses (including reasonable attorneys fees) incurred or suffered by LICENSOR as a result of LICENSEE’S activities in connection with the M.I.T. License or the [*] License, other than liabilities, damages, losses, costs and expenses
incurred in connection with a third party claim alleging the infringement by M.I.T., [*], or LICENSOR of a third party’s intellectual property rights. 
 6. Term and Termination. 
 (a) This Agreement shall become effective upon execution by both parties
and, unless earlier terminated in accordance with its terms, shall continue in effect (i) with regard to the license under the patents included in the Patent Rights, until the expiration of the last to expire of such patents, and (ii) with
regard to the sublicenses, throughout the period that the M.I.T. License or the [*] License is in effect, whichever is longer. Termination of this Agreement shall not affect any rights or obligations which accrue prior to or in connection with such
termination. 
 (b) LICENSEE may terminate this Agreement at any time by giving written notice thereof to LICENSOR. 
 (c) Either party shall have the right to terminate this Agreement in the event the other party breaches any material provision of this Agreement and
fails to cure such breach within thirty (30) days after being notified thereof in writing by the notifying party. 
 (d) Each of M.I.T.
and [*] hereby grant to LICENSEE an option to acquire all of LICENSOR’s rights, subject to all of its obligations, under the M.I.T. License or the [*] License, as the case may be, without giving effect to any breach thereof by LICENSOR (the
“License Rights”), which option shall be exercisable at any time within sixty (60) days after receipt by LICENSEE of a copy of any notice of termination properly given to LICENSOR terminating for any reason whatsoever the M.I.T.
License or the [*] License, as the case may be, after any period for cure provided under such license has passed without LICENSOR having cured. Each of M.I.T. and [*] hereby grant to LICENSEE a license to use the relevant License Rights in
accordance with the provisions of the M.I.T. License or the [*] License, as the case may be, until such option lapses unexercised. 
 (e)
Each of M.I.T. and [*] hereby agree that a copy of any notice given under the M.I.T. License or the [*] License, as the case may be, by M.I.T. or [*] to LICENSOR which may affect LICENSEE’s rights and obligations as a sublicensee under such
license, shall be given to LICENSEE at One Kendall Square, Building 700, Cambridge, Massachusetts 02139, Attention: President, or at such other address as may be requested by LICENSEE in accordance with the notice provisions of the M.I.T. License or
the [*] License, as the case may be. 
 7. Warranties. LICENSOR hereby represents and warrants that (a) LICENSOR is the owner of
all right, title and interest in and to the Patent Rights, and (b) LICENSOR has full power and authority to enter into this License Agreement and to perform the transactions contemplated hereby, including all power and authority to grant the
sublicenses under the M.I.T. License and the [*] License, subject to the consents of M.I.T. and [*] EXCEPT AS EXPRESSLY SET FORTH HEREIN, LICENSOR MAKES NO EXPRESS OR IMPLIED WARRANTIES IN RELATION TO THE PATENT RIGHTS OR THE M.I.T. LICENSE OR

  

 * – Confidential Treatment Requested 

 
THE [*] LICENSE, AND DISCLAIMS ALL IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION ANY IMPLIED WARRANTIES OF MERCHANTABILITY, OF FITNESS FOR A PARTICULAR
PURPOSE, AND AGAINST INFRINGEMENT. 
 8. Publicity. Neither party shall make any announcement, news release, publication, presentation
or any other public disclosure pertaining to this Agreement except (a) as required by law, (b) during the course of or in connection with any litigation, arbitration or other legal proceeding, to the extent based upon or related to the
subject matter of this Agreement, or (c) to the extent required in order to pursue regulatory or other governmental approval of a product or its marketing, without in any such case the prior written approval of the other party, which approval
shall not be unreasonably withheld. 
 9. Assignment and Sublicensing. LICENSEE may assign or sublicense this Agreement or any rights
or obligations hereunder, without the prior written consent of LICENSOR; provided, however, that LICENSEE shall not assign or sublicense this Agreement or any rights or obligations hereunder to any company which engages in any research, development,
commercialization or other activity in any of the areas (i) - (iv) excluded from the definition of Licensed Field under Paragraph 1(d). LICENSEE shall not assign or sublicense this Agreement or any rights or obligations hereunder to the extent such
assignment or sublicense relates to the [*] License, without the prior written consent of [*] 
 10. Severability. If any portion of
this Agreement is deemed to be invalid, illegal or unenforceable by a court or governmental authority of competent jurisdiction, the remaining portions of this Agreement shall not be affected thereby and shall remain in full force and effect.

 11. Entire Agreement. This Agreement contains the entire agreement of the parties with respect to its subject matter and may only
be modified by a writing signed by the parties. 
 12. Governing Law. This Agreement shall be governed by and construed in accordance
with the laws of the State of Illinois, not including its conflict of laws rules. 
 13. Dispute Resolution. The parties shall discuss
and attempt to resolve in good faith any dispute which arises under this License Agreement. If they are unable to resolve the dispute within thirty (30) days after delivery of written notice of, the dispute from one party to the other, either
party may seek to resolve it by bringing legal action in court or by initiating an Alternative Dispute Resolution (“ADR”) in accordance with the provisions set forth in Exhibit B attached hereto and made a part hereof. 
  

 * – Confidential Treatment Requested 

 IN WITNESS WHEREOF, the parties have entered into this Agreement as of the date first above set forth. 
  

									
	 ABBOTT BIOTECH, INC.
	 		 	REPLIGEN CORPORATION
					
	By:	 	 /s/ Gary P. Coughlan
	 		 	By:	 	 /s/ W. Herlihy

	Title:	 	President	 		 	Title:	 	President and CEO

  

 * – Confidential Treatment Requested 

 MASSACHUSETTS INSTITUTE OF TECHNOLOGY consents to the above parties entering into the sublicense under the M.I.T. License
and agree to the provisions of Sections 2(b), 3, 6(d) and 6(e) hereof insofar as they purport to bind it. 
  

			
	By:	 	 /s/ George Dummer

	Title:	 	Director, OSP
	Date:	 	4/28/92

 [*], consents to the above parties entering into the sublicense under the [*] License and agrees to the
provisions of Sections 2(b), 3, 6(d) and 5(e) hereof insofar as they purport to bind it. 
  

			
	 By:
	 	  

	 Title:
	 	  

	 Date:
	 	  

  

 * – Confidential Treatment Requested 

 EXHIBIT A 
 I. Patent Applications (including U.S. and foreign counterparts): 
  

			
	 Case (DBH#s)
	 	 Subject

	 508
	 	[*]
	 509
	 	[*]
	 556
	 	[*]
	 588
	 	[*]
	 600
	 	[*]

 II. Patents (including U.S. and foreign counterparts): 
  

			
	 U.S. Patent #
	 	 Subject

	 4,724,206
	 	Protein Production in Hypertonic Media

  

 * – Confidential Treatment Requested 

 EXHIBIT B 
 ALTERNATE DISPUTE RESOLUTION 
 1. A party may seek to resolve a dispute by initiating an Alternative Dispute
Resolution (“ADR”) with the Center for Public Resources (“CPR”), New York, New York. The parties shall be bound by the forum so chosen for the dispute, except that either party shall have the unrestricted right at any time to
seek a preliminary injunction or other preliminary relief in court if in its judgment such action is necessary to avoid irreparable damage. 
 2. An ADR
shall be initiated by a party by sending written notice thereof to the other party and to the CPR, which notice shall state the issues to be resolved. Within ten (10) business days after the date of such notice, the other party may, by sending
written notice to the party initiating ADR and the CPR, add issues to be resolved in the dispute. Within twenty (20) business days after the date of the original ADR notice, the CPR shall have contacted members of its Panels of Distinguished
Neutrals and acquainted them with the pertinent details of the dispute and the identity of the parties and their counsel, and the CPR shall have nominated to the parties no fewer than five (5) nominees who are qualified and free of conflicts
with the parties and their counsel. The parties shall have five (5) business days after the receipt of such nominations to agree upon a neutral to resolve the dispute or, failing to agree, to rank-order their preferences with the most preferred
neutral being given the lowest number, striking any nominee unacceptable to them, and to mail the rank-order to the CPR. The CPR shall then notify the parties of their selection. If all nominees are unacceptable to a party, the procedure shall be
repeated and, if the parties cannot select a neutral as described above the second time, the CPR shall select the neutral from among its Panelists, which selection shall be final. 
 3. The neutral shall hold a hearing to resolve the issues within sixty (60) business days after selection. Each party may be represented by counsel. The hearing shall be governed by the United States Arbitration
Act. Except as provided by such Act, the neutral shall have sole discretion regarding the scope of discovery, the admissability of evidence and the conduct of the hearing. At least fifteen (15) business days prior to the hearing, each party
shall submit to the other and the neutral a list of all documents on which such party intends to rely at the hearing, a list of all witnesses which such party intends to call at the hearing, and a brief summary of each witness’ testimony. At
least five (5) business days prior to the hearing, each party must submit in writing to the neutral and serve on the other party a proposed ruling on each issue. Such writing shall be limited to the proposed rulings, shall contain no argument
on or analysis of the facts or issues, and shall not be more than fifty (50) pages. Within five (5) business days after the close of the hearing, each party may submit a brief (up to 10 pages) to the neutral addressing the evidence and
issues. 
 4. The neutral shall render the ruling as expeditiously as possible after the hearing. The neutral shall rule on each issue. The neutral’s
ruling shall be final and not appealable, except that either party shall have the right to appeal such ruling on the basis that it was affected by fraud, bad faith or abuse of discretion in connection with the ADR proceedings. A judgment upon the
neutral’s ruling may be entered in any court having jurisdiction thereof. The neutral shall be paid a reasonable fee plus expenses, and the neutral shall determine the proportions in which the parties shall pay such fee and expenses, as well as
the standard charges of the CPR for its assistance in the selection process. If the dispute is resolved by the parties prior to a ruling by the neutral, such fees, expenses and charges shall be borne equally by the parties or as the parties may
otherwise agree. 
  

 * – Confidential Treatment Requested 

 Exhibit B 
 SUBLICENSE AGREEMENT 
 This Sublicense Agreement (this “Agreement”) is effective as
of September 10, 2007 (the “Effective Date”) by and among Repligen Corporation, a corporation organized and existing under the laws of the State of Delaware, having offices at 41 Seyon Street, Building #1, Suite 100 Waltham,
Massachusetts 02453 (“Repligen”), Massachusetts Institute of Technology, a Massachusetts corporation, with a principal office at 77 Massachusetts Avenue, Cambridge, Massachusetts 02139-4307 (“M.I.T.”), and ImClone
Systems Incorporated, a corporation organized and existing under the laws of the State of Delaware, having offices at 180 Varick Street, New York, New York 10014 (“ImClone”). 
 RECITALS: 
 WHEREAS, M.I.T. owns and has exclusively licensed Repligen
under the Sublicensed Patents Rights (as such term is defined below); 
 WHEREAS, Repligen and ImClone are concurrently entering
into the Settlement Agreement and Mutual Release (the “Settlement Agreement”); and 
 WHEREAS, in connection with the
Settlement Agreement, ImClone desires to obtain a worldwide sublicense under the Licensed Patent Rights, and Repligen and M.I.T. desire for Repligen to grant such a sublicense, each under the terms and conditions set forth in this Agreement.

 NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants herein contained, the Parties hereby agree as
follows: 
 1. DEFINITIONS. 
 The
terms used in this Agreement have the following meaning: 
 “Affiliate” means any corporation, firm, partnership or other entity,
whether de jure or de facto, which directly or indirectly through one or more intermediaries controls, is controlled by or is under common control with an entity. An entity shall be deemed to control another entity if it (i) owns, directly or
indirectly, fifty percent (50%) or more of the outstanding voting securities or capital stock (or such lesser percentage which is the maximum allowed to be owned by a foreign corporation in a particular jurisdiction) of such other entity, or
(ii) has other comparable ownership interest with respect to any entity other than a corporation. 
 “Sublicensed Field” shall
mean any application or use without limitation. 
 “Sublicensed Patent Rights” shall mean US Patent 4,663,281 as well as all patent
applications and patents issuing thereon or claiming priority to such Patents, together with any division, continuation, continuation-in-part or the like thereof and any foreign patent application or equivalent corresponding thereto and any letters
patent or the equivalent thereof issuing thereon or reissue, re-examination or extension thereof or Supplementary Protection Certificate or the like in respect thereof. 
 “Sublicensed Product” shall mean any product, composition of matter, system or apparatus which, but for this Agreement, would otherwise infringe a valid claim of an unexpired patent included in the
Sublicensed Patent Rights. 
  

 * – Confidential Treatment Requested 

 “Sublicensed Processes” shall mean any process, method, or method of use which, but for this
Agreement, would otherwise infringe a valid claim of an unexpired patent in the Sublicensed Patent Rights. 
 “Party” means
ImClone, Repligen and M.I.T., individually, and “Parties” means ImClone, Repligen and M.I.T. collectively. 
 “Patents”
means patent applications and patents, together with any division, continuation, continuation-in-part or the like thereof and any foreign patent application or equivalent corresponding thereto and any letters patent or the equivalent thereof issuing
thereon or reissue, re-examination or extension thereof or Supplementary Protection Certificate or the like in respect thereof. 
 “Person” shall mean any natural person, corporation, firm, business trust, joint venture, association, organization, company, partnership or other business entity, or any government or any agency or political subdivision thereof.

 “Supplementary Protection Certificate” shall mean the supplementary protection certificate for Medicinal products provided under
Council Regulation (EEC) No. 1768/92 of June 18, 1992 and their equivalents. 
 “Territory” shall mean the entire world.

 “Third Party” shall mean any party other than Repligen, ImClone, M.I.T. or their respective Affiliates. 
 Interpretative Rules. For the purpose of this Agreement, except as otherwise expressly provided herein or unless the context otherwise requires:
(a) defined terms include the plural as well as the singular and the use of any gender shall be deemed to include the other gender; (b) references to Articles, Sections and other subdivisions and to Schedules and Exhibits without reference
to a document, are to designated Articles. Sections and other subdivisions of and to Schedules and Exhibits to this Agreement; (c) the use of the term “including” means “including but not limited to”; and (d) the words
“herein”, “hereof”, “hereunder” and other words of similar import refer to this Agreement in whole and not to any particular provision. 
 2. GRANT OF SUBLICENSE. 
 2.1 Sublicense. 
 (a) Repligen hereby grants to ImClone, as well as its present and future Affiliates, a non-exclusive, royalty-free, fully paid-up, perpetual, irrevocable,
except as explicitly provided in Section 4.2, sublicense throughout the Territory under the Sublicensed Patent Rights: (i) to use, make, have made, import, offer to sell, sell, market, promote, distribute, develop and/or commercialize
Sublicensed Products in the Sublicensed Field, without the right to grant sublicenses; and (ii) to practice, have practiced, use, sell and/or commercialize Sublicensed Processes in the Sublicensed Field, without the right to grant sublicenses.
Without limiting the foregoing, Repligen and M.I.T. each acknowledge and agree (1): that the foregoing sublicense covers, and is hereby extended to, (A) [*], their respective Affiliates and sublicensees pursuant to the terms and conditions of
such agreements ImClone has entered into with such parties, as amended and as may be amended from time to time, and (B) any other collaboration partners, sublicensees and subsublicensees of ImClone relating to Sublicensed Products and/or
Sublicensed Processes in the Sublicensed Field throughout the Territory pursuant to the terms and condition of such agreements ImClone may have with such parties for the commercialization of ImClone products; and (2) the foregoing sublicense
grant covers any and all past activities of (A) ImClone, (B) ImClone’s present and past Affiliates, and (C) present and past collaboration partners, licensees and sublicensees relating to Sublicensed Products and/or Sublicensed
Processes in the Sublicensed Field throughout the Territory for the commercialization of ImClone products. 
  

 * – Confidential Treatment Requested 

 (b) Except as expressly set forth pursuant to this Section 2.1, ImClone shall not acquire any
license or other intellectual property interest under this Agreement, by implication or otherwise, including Patents, know-how, trademarks or copyrights owned or licensed by Repligen, M.I.T. or their respective Affiliates. 
 3. REPRESENTATIONS AND WARRANTIES. 
 3.1 As of
the Effective Date, Repligen and M.I.T. each represent and warrant to ImClone that they have the full right, power and authority to enter into this Agreement, and that Repligen has the authority to grant the sublicenses granted under
Section 2.1 hereof. 
 3.2 As of the Effective Date, ImClone represents and warrants to Repligen and M.I.T. that ImClone has the full
right, power and authority to enter into this Agreement. 
 3.3 As of the Effective Date, Repligen and M.I.T. each represent to ImClone that
they are respectively licensee and owner of US Patent 4,663,281. EXCEPT AS EXPRESSLY SET FORTH HEREIN, REPLIGEN MAKES NO EXPRESS OR IMPLIED WARRANTIES IN RELATION TO THE ‘281 PATENT AND DISCLAIMS ALL IMPLIED WARRANTIES, INCLUDING WITHOUT
LIMITATION, ANY IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, AND AGAINST INFRINGEMENT. 
 3.4 M.I.T. and
Repligen covenant and agree that the agreement under which M.I.T. exclusively licensed Repligen is in full force and effect as of the Effective Date of this Agreement, and further that in the event of termination or invalidity of the M.I.T.
agreement that the present sublicense to ImClone granted in this Sublicense Agreement shall survive such termination and/or invalidity and remain in force as if and to the same extent that it would have if the M.I.T. agreement were still in force.

 4. TERM; TERMINATION. 
 4.1
Term and Expiration. This Agreement shall be effective as of the Effective Date and shall continue perpetually, unless otherwise earlier terminated under Section 4.2 of this Agreement. 
 4.2 Termination of this Agreement. This Agreement shall not be terminable by any Party, with or without cause, without the written consent of both
other Parties. 
 5. MISCELLANEOUS. 
 5.1 Continued Rights upon Bankruptcy. All rights and sublicenses granted under or pursuant to any section of this Agreement are and shall otherwise be deemed to be for purposes of Section 365(n) of Title 11, United States Code
(the “Bankruptcy Code”) licenses of rights to “intellectual property” as defined in Section 101(56) of the Bankruptcy Code. The Parties shall retain and may fully exercise all of their respective rights and elections under
the Bankruptcy Code. Upon the bankruptcy of any Party, the non-bankrupt Parties shall further be entitled to a complete duplicate of, or complete access to all documents embodying, any such intellectual property or relating to obtaining protection
of or maintaining same, and such, if not already in its possession, shall be promptly delivered to the non-bankrupt Parties, unless the bankrupt Party elects to continue, and continues, to perform all of its obligations under this Agreement.

  

 * – Confidential Treatment Requested 

 5.2 Assignment/Change of Control. Except as provided in this Section 5.2, this Agreement may
not be assigned or otherwise transferred, nor may any right or obligation hereunder be assigned or transferred, by either Party without the written consent of the other Party; provided, however, that either Party may, without such consent, assign
this Agreement and all or substantially all of its rights and obligations hereunder to: (a) an Affiliate of such Party; or (b) any Third Party in connection with the transfer or sale to such Third Party of all or substantially all of its
rights to Sublicensed Product or Sublicensed Process; or (c) a Third Party that acquires, whether by sale, merger, recapitalization or other business combination, all or substantially all of the assets or businesses of ImClone; or (d) any
Third Party if such Third Party is a person or group other than the current controlling person or group and which Third Party shall effectively acquire control of the management and policies of such Party; or (e) a Third Party in association
with a sale of all product rights relating to Erbitux. Any attempted assignment not in accordance with this Section 5.2 shall be void. Any permitted assignee shall assume in writing all assigned obligations of its assignor under this Agreement.

 5.3 Severability. If any one or more of the provisions contained in this Agreement is held invalid, illegal or unenforceable in any
respect, the validity, legality and enforceability of the remaining provisions contained herein shall not in any way be affected or impaired thereby. In the event that the absence of the invalidated provision(s) adversely affects the substantive
rights of the Parties, the Parties shall use their best efforts to replace the invalid, illegal or unenforceable provision(s) with valid, legal and enforceable provision(s) which, insofar as practical, implement the purposes of this Agreement.

 5.4 Notices. All notices which are required or permitted hereunder shall be in writing and either delivered personally, sent by
facsimile (and promptly confirmed by personal delivery, registered or certified mail or overnight courier), sent by internationally-recognized overnight courier or sent by registered or certified mail, postage prepaid, return receipt requested,
addressed as follows: 
 All notices and other communication to Repligen must be sent to: 
 Repligen Corporation 
 41 Seyon Street

 Building #1, Suite 100 
 Waltham, MA 02453 
 Attention: President and Chief Executive Officer 
 All notices and other communications to ImClone must be sent to: 
 ImClone Systems Incorporated 
 180 Varick Street 
 New York, NY 10014 
 Attention: General
Counsel 
 All notices and other communications to ImClone must be sent to: 
 Technology Licensing Office, Room NE25-230 
 Massachusetts Institute of Technology 
 77 Massachusetts Avenue 
 Cambridge, MA 02139-4307 
 Attention:
Director, Technology Licensing Office 
 or to such other address(es) as the Party to whom notice is to be given may have furnished to the other Party in
writing in accordance herewith. Any such notice shall be deemed to have been given: (a) when delivered, if personally delivered or sent by facsimile on a business day (or if delivered or sent on a non-business day, then on the next business
day); (b) on the business day after dispatch, if sent by nationally-recognized overnight courier; or (c) on the fifth (5th) business day following the date of mailing, if sent by mail. 
  

 * – Confidential Treatment Requested 

 5.5 Applicable Law. This Agreement shall be governed by and construed in accordance with the laws
of the Commonwealth of Massachusetts without regard to conflicts of laws principles and the patent laws of the relevant jurisdiction of a patent included within the Sublicensed Patent Rights, without reference to any rules of conflict of laws or
renvoi. 
 5.6 Entire Agreement; Amendments. This Agreement contains the entire understanding of the Parties with respect to the
Sublicensed Patent Rights in the Sublicensed Field and the sublicenses granted, and rights retained, hereunder relating to Sublicensed Products and Sublicensed Processes. This Agreement may be amended, or any term hereof modified, only by a written
instrument duly executed by authorized representatives of the Parties hereto. 
 5.7 Headings. The captions to the Sections hereof are
not a part of this Agreement, but are merely for convenience to assist in locating and reading the Sections hereof. 
 5.8 Independent
Contractors. It is expressly agreed that Repligen, M.I.T. and ImClone shall be independent contractors and that the relationship between the Parties shall not constitute a partnership, joint venture or agency. None of Repligen, M.I.T. or ImClone
shall have the authority to make any statements, representations or commitments of any kind, or to take any action, which shall be binding on another Party, without the prior written consent of such other Party. 
 5.9 Waiver. The waiver by any Party hereto of any right hereunder, or of any failure of any other Party to perform, or of any breach by any other
Party, shall not be deemed a waiver of any other right hereunder or of any other breach by or failure of such other Party, whether of a similar nature or otherwise. 
 5.10 Cumulative Remedies. No remedy referred to in this Agreement is intended to be exclusive, but each shall be cumulative and in addition to any other remedy referred to in this Agreement or otherwise
available under law. 
 5.11 Waiver of Rule of Construction. Each Party has had the opportunity to consult with counsel in connection
with the review, drafting and negotiation of this Agreement. Accordingly, the rule of construction that any ambiguity in this Agreement shall be construed against the drafting Party shall not apply. 
 5.12 Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument. 
 *    *    * 
  

 * – Confidential Treatment Requested 

 IN WITNESS WHEREOF, the Parties have entered into this Agreement as of the Effective Date. 
  

			
	Repligen Corporation
		
	By:	 	 /s/ Walter Herlihy

		 	Walter C. Herlihy, PhD
		 	President and Chief Executive Officer

  

			
	Massachusetts Institute of Technology
		
	By:	 	 /s/ Lita Nelsen

		 	Lita L. Nelsen
		 	Director, Technology licensing Office

  

			
	ImClone Systems Incorporated
		
	By:	 	 /s/ Daniel J. O’Connor

		 	Daniel J. O’Connor
		 	General Counsel, Sr. Vice President and Secretary

  

 * – Confidential Treatment Requested 

 Exhibit C 
 SUBLICENSE AGREEMENT 
 This Sublicense Agreement (this “Agreement”) is effective as
of September 10, 2007 (the “Effective Date”) by and between Repligen Corporation, a corporation organized and existing under the laws of the State of Delaware, having offices at 41 Seyon Street, Building #1, Suite 100 Waltham,
Massachusetts 02453 (“Repligen”), and ImClone Systems Incorporated, a corporation organized and existing under the laws of the State of Delaware, having offices at 180 Varick Street, New York, New York 10014
(“ImClone”). 
 RECITALS: 
 WHEREAS, Repligen has licensed and/or sublicensed certain patent rights from Abbott Laboratories, an Illinois corporation, having a principal place of business at 100 Abbott Park Road, Abbott Park, Illinois
60064-3500, and/or Affiliates of Abbott Laboratories (including, without limitation, Abbott Biotech, Inc.), (“Abbott”), pursuant to that certain Technology License Agreement entered into by Abbott Biotech, Inc. and Repligen on
May 14, 1992, as amended (“TLA”), including the right to sublicense under certain terms and restrictions provided in the TLA; 
 WHEREAS, Repligen and ImClone are concurrently entering into the Settlement Agreement and Releases (the “Settlement Agreement”); and 
 WHEREAS, in connection with the Settlement Agreement, ImClone desires to obtain from Repligen a worldwide sublicense under the Sublicensed Patent Rights (as defined below), and Repligen desires to grant such a
sublicense, each under the terms and conditions set forth in this Agreement. 
 NOW, THEREFORE, in consideration of the foregoing
premises and the mutual covenants herein contained, the Parties hereby agree as follows: 
 1. DEFINITIONS. 
 The terms used in this Agreement have the following meaning: 
 “Affiliate” means (a) any corporation, firm, partnership or other entity, whether de jure or de facto, which directly or indirectly through one or more intermediaries controls, is controlled by or is
under common control with an entity. An entity shall be deemed to control another entity if it (i) owns, directly or indirectly, fifty percent (50%) or more of the outstanding voting securities or capital stock (or such lesser percentage
which is the maximum allowed to be owned by a foreign corporation in a particular jurisdiction) of such other entity, or (ii) has other comparable ownership interest with respect to any entity other than a corporation. 
 The “Excluded Field” shall mean the application or use [*]. 
 “Licensed Field” shall mean any application or use with the exception of the Excluded Field. 
 “Licensed Product” shall mean any product, composition of matter, system or apparatus which, but for this Agreement, would otherwise infringe a valid claim of an unexpired patent included in the Sublicensed Patent Rights.

  

 * – Confidential Treatment Requested 

 “Licensed Processes” shall mean any process, method, or method of use which, but for this
Agreement, would otherwise infringe a valid claim of an unexpired patent in the Sublicensed Patent Rights. 
 “Party” means ImClone
and Repligen, individually, and “Parties” means ImClone and Repligen, collectively. For the avoidance of doubt, Abbott is not included within the definition of “Party”. 
 “Patents” means all United States patents and patent applications and all corresponding foreign patents and patent applications, including any
and all divisions, continuations, continuations-in-part, reissues and extensions thereof that exist now or that come into existence in the future, and relevant information and documentation contained in the patent file history. 
 “Person” shall mean any natural person, corporation, firm, business trust, joint venture, association, organization, company, partnership or
other business entity, or any government or any agency or political subdivision thereof. 
 “Sublicensed Patent Rights” shall mean
(a) U.S. Patent No. 5,665,578 and U.S. Patent 5,741,682, and (b) all Patents issuing on or claiming priority to the Patents described in clause (a). 
 “Territory” shall mean the entire world. 
 “Third Party” shall mean any party other than
Repligen, ImClone or their respective Affiliates. 
 Interpretative Rules. For the purpose of this Agreement, except as otherwise expressly
provided herein or unless the context otherwise requires: (a) defined terms include the plural as well as the singular and the use of any gender shall be deemed to include the other gender; (b) references to Articles, Sections and other
subdivisions and to Schedules and Exhibits without reference to a document, are to designated Articles. Sections and other subdivisions of and to Schedules and Exhibits to this Agreement; (c) the use of the term “including” means
“including but not limited to”; and (d) the words “herein”, “hereof”, “hereunder” and other words of similar import refer to this Agreement in whole and not to any particular provision. 
 2. GRANT OF SUBLICENSE. 
 2.1
Sublicense. 
 (a) Repligen hereby grants to ImClone, as well as present and future Affiliates of ImClone, a non-exclusive,
royalty-free, fully paid-up, perpetual, irrevocable (except as explicitly provided in Section 4.2), sublicense throughout the Territory under the Sublicensed Patent Rights: (i) to use, make, have made, import, offer to sell, sell, market,
promote, distribute, develop and/or commercialize Licensed Products in the Licensed Field, excluding the right to grant sublicenses; and (ii) to practice, have practiced, use, sell and/or commercialize Licensed Processes in the Licensed Field,
excluding the right to grant sublicenses. 
 (b) ImClone acknowledges that the rights under the TLA that are sublicensed to ImClone hereunder
do not and cannot exceed the scope of Repligen’s rights under the TLA. Except as expressly set forth pursuant to this Section 2.1, ImClone shall not acquire any license or other intellectual property interest under this Agreement, by
implication or otherwise, including Patents, know-how, trademarks or copyrights owned or licensed by Repligen or its Affiliates. 
 (c) All
rights granted by Repligen to ImClone are granted under Paragraph 2(a), and not Paragraph 2(b), of the TLA. 
 (d) During the term of this
Agreement ImClone, as required pursuant to the terms of its contracts with collaboration or manufacturing partners, may at any time, and from time to time, give notice to Repligen regarding ImClone’s desire that Repligen grant another
sublicense under the 

  

 * – Confidential Treatment Requested 

 
Sublicensed Patent Rights, which sublicense would be granted to a collaboration partner or a manufacturing partner for Erbitux existing at the time such
notice is given, (each such partner, a “New Sublicensee”). Within 30 days of receiving such a notice, subject to reasonable assurances that the proposed New Sublicensee can make the representations and warranties required below to comply
with the restrictions of the TLA, Repligen shall provide such New Sublicensee (with a copy to ImClone) with a sublicense agreement duly executed by Repligen in the same form as this Agreement provided that (a) Repligen and such New Sublicensee
shall be parties to such sublicense (ImClone will not be party), with the sublicense running from Repligen to such New Sublicensee, and (b) such sublicense grant shall be limited by adding to the end the phrase “; provided in each case
only with regard to Erbitux and/or its manufacture, and not with regard to any other products or manufacture of any such other products.” For the avoidance of doubt, in such sublicense agreement, such New Sublicensee shall make to Repligen the
same representations and warranties made by ImClone to Repligen under this Agreement, including without limitation those representations, warranties and contract terms made and agreed to in connection with confirming that such New Sublicensee is and
remains a permitted sublicensee under Paragraph 9 of the TLA. Upon each such New Sublicensee executing such sublicense agreement provided to it by Repligen, each such New Sublicensee shall be sublicensed under the Sublicensed Patent Rights pursuant
to the terms and conditions of such sublicense agreement. 
 3. REPRESENTATIONS AND WARRANTIES. 
 3.1 As of the Effective Date, consistent with the rights and restrictions to which Repligen is subject to under the TLA, Repligen represents and warrants
to ImClone that Repligen has the full right, power and authority to enter into this Agreement, and to grant the sublicense to ImClone under Section 2.1(a) or any other sublicenses which may be granted under Section 2.1(d) hereof.

 3.2 ImClone represents and warrants that it and its Affiliaties have the full right and authority to accept and be bound by the conditions
and restrictions of the TLA applicable to sublicensees. ImClone further represents and warrants that it and its Affiliates are not engaged, and have no current intent to engage in the future, in any research, development, commercialization or other
activity in any of the areas of: [*]. EXCEPT AS EXPRESSLY SET FORTH HEREIN, IMCLONE MAKES NO EXPRESS OR IMPLIED WARRANTIES AND DISCLAIMS ALL IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A
PARTICULAR PURPOSE, AND AGAINST INFRINGEMENT. 
 3.3 Repligen represents and warrants that (i) to the best of Repligen’s knowledge
and belief, Repligen has provided ImClone with a complete and accurate copy of the TLA in effect as of the Effective Date, (ii) to the best of Repligen’s knowledge and belief, the TLA is in full force and effect as of the Effective Date,
(iii) to the best of Repligen’s knowledge and belief, no party to the TLA is in material breach of the TLA as of the Effective Date and Repligen is not aware of any circumstance that would give rise to material breach of the TLA as of the
Effective Date, (iv) no party to the TLA has notified in writing any other party to the TLA of any material breach of the TLA that remains uncured as of the Effective Date, and (v) Repligen has not voluntarily terminated the TLA pursuant
to Paragraph 6(b) of the TLA or otherwise terminated the TLA by mutual agreement with Abbott. 
 3.4 EXCEPT AS EXPRESSLY SET FORTH IN
SECTIONS 3.1, OR 3.3, REPLIGEN MAKES NO EXPRESS OR IMPLIED WARRANTIES AND DISCLAIMS ALL IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, AND AGAINST INFRINGEMENT.

 3.5 Repligen hereby covenants and agrees that: 
 (i) to the extent it is within Repligen’s control (a) it will maintain and not terminate, invalidate, encumber or diminish the TLA and/or the patents sublicensed thereunder, and (b) it will not modify
or amend (or consent to modification or amendment of) the TLA, in each case only insofar as it affects the rights and obligations of Repligen thereunder with respect to rights and obligations of ImClone under this Agreement, without the written
permission of ImClone; and 
  

 * – Confidential Treatment Requested 

 (ii) any assignment of the TLA by Repligen is subject to this Agreement and ImClone shall be promptly
provided with written notice of such assignment; 
 (iii) it will promptly provide ImClone with any notice of material breach of the TLA
and/or intent to terminate the TLA and/or the rights and sublicenses thereunder, to the extent Repligen is aware of the foregoing, and it shall use commercially reasonable efforts to attempt to cure any such breach and/or to prevent termination of
such TLA and/or such rights and licenses thereunder, except to the extent caused by ImClone or its Affiliates; and if Repligen fails to promptly do so, ImClone shall have the right, but not the obligation, to cure such breach and/or prevent such
termination; and 
 (iv) in the event that Repligen receives any notice from Abbott regarding any actual or alleged breach of the TLA,
Repligen shall promptly provide such notice to ImClone, and thereafter keep ImClone promptly and fully informed regarding all material communications between Abbott and Repligen regarding such breach. 
 3.6 EXCEPT AS EXPRESSLY SET FORTH IN SECTIONS 3.2, IMCLONE MAKES NO EXPRESS OR IMPLIED WARRANTIES AND DISCLAIMS ALL IMPLIED WARRANTIES, INCLUDING WITHOUT
LIMITATION, ANY IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, AND AGAINST INFRINGEMENT. 
 4. TERM; TERMINATION. 

 4.1 Term and Expiration. This Agreement shall be effective as of the Effective Date and shall continue until the TLA expires
pursuant to paragraph 6(a) of the TLA unless otherwise terminated earlier under Section 4.2 of this Agreement. 
 4.2 Termination of
this Agreement. This Agreement shall not be terminable by either Party, with or without cause, without the other Party’s written consent, except as explicitly provided in this Agreement; provided that in the event that ImClone falls out of
compliance with the restrictions set forth in para. 9 of the TLA, this Agreement and the sublicense granted hereunder shall automatically terminate. 
 5.
MISCELLANEOUS. 
 5.1 Continued Rights upon Bankruptcy. All rights and licenses granted under or pursuant to any section of
this Agreement are and shall otherwise be deemed to be for purposes of Section 365(n) of Title 11, United States Code (the “Bankruptcy Code”) licenses of rights to “intellectual property” as defined in Section 101(56)
of the Bankruptcy Code. The Parties shall retain and may fully exercise all of their respective rights and elections under the Bankruptcy Code. Upon the bankruptcy of any Party, the non-bankrupt Party shall further be entitled to a complete
duplicate of, or complete access to all documents embodying, any such intellectual property or relating to obtaining protection of or maintaining same, and such, if not already in its possession, shall be promptly delivered to the non-bankrupt
Party, unless the bankrupt Party elects to continue, and continues, to perform all of its obligations under this Agreement. 
 5.2
Assignment/Change of Control. Except as provided in this Section 5.2, this Agreement may not be assigned or otherwise transferred, nor may any right or obligation hereunder be assigned or transferred, by either Party without the written
consent of the other Party; provided, however, that either Party may, without such consent, assign this Agreement and all or substantially all of its rights and obligations hereunder to: (a) an Affiliate of such Party; or (b) any Third
Party in connection with the transfer or sale to such Third Party of all or substantially all of its rights to Licensed Product or Licensed Process; or 

  

 * – Confidential Treatment Requested 

 
(c) a Third Party that acquires, whether by sale, merger, recapitalization or other business combination, all or substantially all of the assets or
businesses of ImClone; or (d) any Third Party if such Third Party is a person or group other than the current controlling person or group and which Third Party shall effectively acquire control of the management and policies of such Party; or
(e) a Third Party in association with a sale of all product rights relating to Erbitux, provided that the assignment is in compliance with the conditions and restrictions of the TLA. Any attempted assignment not in accordance with this
Section 5.2 shall be void. Any permitted assignee shall assume in writing all assigned obligations of its assignor under this Agreement. 
 5.3 Severability. If any one or more of the provisions contained in this Agreement is held invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained herein shall
not in any way be affected or impaired thereby. In the event that the absence of the invalidated provision(s) adversely affects the substantive rights of the Parties, the Parties shall use their best efforts to replace the invalid, illegal or
unenforceable provision(s) with valid, legal and enforceable provision(s) which, insofar as practical, implement the purposes of this Agreement. 
 5.4 Notices. All notices which are required or permitted hereunder shall be in writing and either delivered personally, sent by facsimile (and promptly confirmed by personal delivery, registered or certified mail or overnight
courier), sent by internationally-recognized overnight courier or sent by registered or certified mail, postage prepaid, return receipt requested, addressed as follows: 
 All notices and other communication to Repligen must be sent to: 
 Repligen Corporation 
 41 Seyon Street 
 Building #1, Suite 100

 Waltham, MA 02453 
 Attention: President and CEO 
 All notices and other communications to ImClone must be sent to: 
 ImClone Systems Incorporated 
 180 Varick
Street 
 New York, NY 10014 
 Attention: General Counsel 
 or to such other address(es) as the Party to whom notice is to be given may have furnished to the other Party in
writing in accordance herewith. Any such notice shall be deemed to have been given: (a) when delivered, if personally delivered or sent by facsimile on a business day (or if delivered or sent on a non-business day, then on the next business
day); (b) on the business day after dispatch, if sent by nationally-recognized overnight courier; or (c) on the fifth (5th) business day following the date of mailing, if sent by mail. 
 5.5 Applicable Law. This Agreement shall be governed by and construed in accordance with the laws of the Commonwealth of Massachusetts without
regard to conflicts of laws principles and the patent laws of the relevant jurisdiction of a patent included within the Sublicensed Patent Rights, without reference to any rules of conflict of laws or renvoi. 
 5.6 Entire Agreement; Amendments. This Agreement contains the entire understanding of the Parties with respect to the Sublicensed Patent Rights in
the Field and the licenses granted, and rights retained, hereunder relating to Licensed Products. Any other express or implied agreements and understandings, either oral or written, with regard to the sublicense to ImClone of Sublicensed Patent
Rights in the Field, are superseded by the terms of this Agreement. This Agreement may be amended, or any term hereof modified, only by a written instrument duly executed by authorized representatives of both Parties hereto. 
  

 * – Confidential Treatment Requested 

 5.7 Headings. The captions to the Sections hereof are not a part of this Agreement, but are merely
for convenience to assist in locating and reading the Sections hereof. 
 5.8 Independent Contractors. It is expressly agreed that
Repligen and ImClone shall be independent contractors and that the relationship between the Parties shall not constitute a partnership, joint venture or agency. Neither Repligen nor ImClone shall have the authority to make any statements,
representations or commitments of any kind, or to take any action, which shall be binding on the other Party, without the prior written consent of the other Party. 
 5.9 Waiver. The waiver by either Party hereto of any right hereunder, or of any failure of the other Party to perform, or of any breach by the other Party, shall not be deemed a waiver of any other right
hereunder or of any other breach by or failure of such other Party, whether of a similar nature or otherwise. 
 5.10 Cumulative
Remedies. No remedy referred to in this Agreement is intended to be exclusive, but each shall be cumulative and in addition to any other remedy referred to in this Agreement or otherwise available under law. 
 5.11 Waiver of Rule of Construction. Each Party has had the opportunity to consult with counsel in connection with the review, drafting and
negotiation of this Agreement. Accordingly, the rule of construction that any ambiguity in this Agreement shall be construed against the drafting Party shall not apply. 
 5.12 Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. 
 5.13 Further Actions. Each Party will duly execute and deliver, or cause to be duly executed and delivered, such further instruments and do and
cause to be done such further acts and things, as may be necessary or as the other Party may reasonably request in connection with this Agreement or to carry out more effectively the provisions and purposes, or to better assure and confirm unto such
other Party its rights under this Agreement. 
 If any provision of this Agreement is asserted or alleged by Abbott or held by a court to
render this Agreement as invalid, illegal or unenforceable, in any respect or to any extent, then without limitation to any other right or remedy of a Party hereto, at the request of ImClone: (a) in such respect and to such extent such
provision of this Agreement will be given no effect by the Parties and shall not form part of this Agreement; and (b) if requested by ImClone, to the fullest extent permitted by applicable law, all other provisions of this Agreement shall
remain in full force and effect and the Parties will use their best efforts to negotiate a provision in replacement of the provision held invalid, illegal or unenforceable that is consistent with applicable law and achieves, as nearly as possible,
the original intention of the Parties. 
 If the lack of any provision not in this Agreement is asserted or alleged by Abbott or held by a
court to render this Agreement as invalid, illegal or unenforceable, in any respect or to any extent, then without limitation to any other right or remedy of a Party hereto, at the request of ImClone: (a) in such respect and to such extent the
Parties will use their best efforts to negotiate a provision to be added to this Agreement to remedy the lack of such provision in a manner that is consistent with applicable law and achieves, as nearly as possible, the original intention of the
Parties; and (b) if requested by ImClone, to the fullest extent permitted by applicable law, all other provisions of this Agreement shall remain in full force to the fullest extent permitted by applicable law. 
 *    *    * 
  

 * – Confidential Treatment Requested 

 IN WITNESS WHEREOF, the Parties have entered into this Agreement as of the Effective Date. 
  

									
	Repligen Corporation	 		 	ImClone Systems Incorporated
					
	By:	 	 /s/ Walter Herlihy
	 		 	By:	 	 /s/ Daniel J. O’Connor

		 	Walter Herlihy	 		 		 	Daniel J. O’Connor
		 	President and CEO	 		 		 	SVP, Legal, General Counsel

  

 * – Confidential Treatment Requested 

 Exhibit D 
 UNITED STATES DISTRICT COURT 
 DISTRICT OF MASSACHUSETTS 
  

			
	 MASSACHUSETTS INSTITUTE OF
	  	
	 TECHNOLOGY and REPLIGEN CORPORATION,
	  	
		
	 Plaintiffs,
	  	
		  	Civil Action No. 04-10884-RGS
	 v.
	  	
		
	 IMCLONE SYSTEMS, INC.,
	  	
		
	 Defendant.
	  	

 STIPULATION FOR DISMISSAL 
 Pursuant to Federal Rule of Civil Procedure 41(a)(1)(ii), Plaintiffs Massachusetts Institute of Technology and Repligen Corporation and
Defendant Imclone Systems, Inc. stipulate to the dismissal of this action, including all claims and counterclaims, with prejudice, with each party to bear its own costs and attorneys’ fees. 
 The parties have settled this case pursuant to a Settlement Agreement and request that the Court retain jurisdiction for the purposes of
resolving any disputes arising under the Settlement Agreement. 
  

			
	Dated: September     , 2007	  	  

		
		  	James H. Wallace, Jr.
		  	Mark A. Pacella
		  	Kevin P. Anderson
		  	Robert J. Scheffel
		  	WILEY REIN LLP
		  	1776 K Street, NW
		  	Washington DC 20006
		  	Phone: 202.719.7000
		  	Fax: 202.719.7049
		
		  	Michael R. Gottfried (BBO # 542156)
		  	Anthony J. Fitzpatrick (BBO # 564324)
		  	 Christopher S. Kroon (BBO # 660286)
 DUANE MORRIS LLP

		  	470 Atlantic Avenue, Suite 500
		  	Boston, MA 02210
		  	Phone: 857.488.4200
		  	Fax: 857.488.4201
		
		  	Attorneys for Defendant ImClone Systems Inc.

  

 * – Confidential Treatment Requested 

			
	Dated: September     , 2007	  	  

		
		  	Gregory A. Madera (BBO #313,020)
		  	FISH & RICHARDSON P.C.
		  	225 Franklin Street
		  	Boston, MA 02110-2804
		  	Telephone: (617) 542-5070
		  	Facsimile: (617) 542-8906
		
		  	Jonathan E. Singer
		  	Michael J. Kane
		  	John C. Adkisson
		  	William R. Woodford
		  	 FISH & RICHARDSON P.C.
 3300 Dain Rauscher
Plaza
 60 South Sixth Street

		  	Minneapolis, MN 55402
		  	Telephone: (612) 335-5070
		  	Facsimile: (612) 288-9696
		
		  	Juanita R. Brooks
		  	FISH & RICHARDSON P.C.
		  	12390 El Camino Real
		  	San Diego. CA 92130
		  	Telephone: (858) 678-5070
		  	Facsimile: (858) 678-509
		  	Attorneys for Plaintiffs
		  	 MASSACHUSETTS INSTITUTE OF
 TECHNOLOGY AND
 REPLIGEN CORPORATION

  

 * – Confidential Treatment Requested 

 Exhibit E 
  

					
	 Repli Gen
  
 FOR IMMEDIATE RELEASE
	  		  	 Repligen Corporation
 41 Seyon Street
 Building #1, Suite 100
 Waltham, Massachusetts 02453
 Telephone: 781-250-0111
 Telefax: 781-250-0115

 CONTACT: 
  

			
	 Walter C. Herlihy, Ph.D.
 President and Chief Executive
Officer
 (781) 419-1900
	  	 Laura Whitehouse
 Vice President, Market Development

 (781) 419-1812

 Repligen Announces Settlement with
ImClone in Erbitux ® Lawsuit 
 WALTHAM, MA – September 10, 2007 – Repligen Corporation (NASDAQ: RGEN) announced today it
has reached a settlement with ImClone Systems, Incorporated (NASDAQ: IMCL) in the lawsuit against ImClone for infringement of U.S. Patent No. 4,663,281 based on ImClone’s manufacture and sale of Erbitux ® . The settlement provides for ImClone to make a payment of $65 million to co-plaintiffs Repligen and The Massachusetts Institute of Technology (MIT) and will result in net proceeds to Repligen of approximately $40
million after payment of obligations to MIT and legal expenses. The settlement agreement serves as the basis for Repligen and MIT to dismiss the lawsuit against ImClone and Repligen has granted ImClone a non-exclusive sublicense to certain patent
rights. 
 “We are very pleased by the settlement of this case which will enable us to end this quarter with more than $60 million in cash and cash
equivalents,” stated Walter C. Herlihy, President and Chief Executive Officer of Repligen Corporation. “We plan to invest the proceeds from the settlement in the growth and expansion of both our CNS product pipeline and our bioprocessing
business.” 
 In May 2004, Repligen and MIT filed an action in the United States District Court
for the District of Massachusetts against ImClone for infringement of U.S. Patent No. 4,663,281 based on ImClone’s manufacture and sale of Erbitux ® . The patent, which covers the
use of certain genetic elements that increase protein production in a mammalian cell, is assigned to MIT and exclusively licensed to Repligen. Repligen and MIT were represented in the litigation by Fish and Richardson P.C. 
 About Repligen Corporation 
 Repligen Corporation is a
biopharmaceutical company focused on the development of novel therapeutics for diseases that affect the central nervous system. In addition, we are the world’s leading supplier of recombinant Protein A, the sales of which partially fund the
advancement of our development pipeline while supporting our financial stability. Repligen’s corporate headquarters are located at 41 Seyon Street, Building #1, Suite 100, Waltham, MA 02453. Additional information may be requested from
www.repligen.com . 
 This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of
Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements in this release do not constitute guarantees of future performance. Investors are
cautioned that statements in this press release which are not strictly historical statements, including, without limitation, statements regarding current or future financial performance and position, management’s strategy, plans and objectives
for future operations, plans and objectives for product development, plans and 

  

 * – Confidential Treatment Requested 

 
objectives for present and future clinical trials and results of such trials, plans and objectives for regulatory approval, litigation, intellectual
property, product development, manufacturing plans and performance such as the anticipated growth in the monoclonal antibody market and our other target markets and projected growth in product sales, constitute forward-looking statements. Such
forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation, risks associated with: the success of current and future
collaborative relationships, the market acceptance of our products, our ability to compete with larger, better financed pharmaceutical and biotechnology companies, new approaches to the treatment of our targeted diseases, our expectation of
incurring continued losses, our uncertainty of product revenues and profits, our ability to generate future revenues, our ability to raise additional capital to continue our drug development programs, the success of our clinical trials, our ability
to develop and commercialize products, our ability to obtain required regulatory approvals, our compliance with all Food and Drug Administration regulations, our ability to obtain, maintain and protect intellectual property rights for our products,
the risk of litigation regarding our intellectual property rights, our limited sales and manufacturing capabilities, our dependence on third-party manufacturers and value added resellers, our ability to hire and retain skilled personnel, our
volatile stock price, and other risks detailed in Repligen’s filings with the Securities and Exchange Commission. Repligen assumes no obligation to update any forward-looking information contained in this press release or with respect to the
announcements described herein. 
  

 * – Confidential Treatment Requested 

 Exhibit F 
 IMCLONE SETTLES PATENT LAWSUIT AND GAINS RIGHTS TO 
 ADDITIONAL INTELLECTUAL PROPERTY

 NEW YORK, September 10, 2007 —ImClone Systems Incorporated (NASDAQ: IMCL) today announced that it has signed settlement and sublicensing
agreements with the Massachusetts Institute of Technology (MIT) and Repligen Corporation to end litigation related to U.S. Patent No. 4,663,281 (the “‘281 Patent”), which is owned by MIT and exclusively licensed to Repligen. All
terms of the agreements have been finalized and the parties will submit a stipulation of dismissal to the court. This settlement eliminates the need for the trial proceedings previously scheduled to begin today, as well as any further court
proceedings or decisions relating to damages sought from ImClone by MIT and Repligen with respect to the ‘281 Patent. 
 Pursuant to the terms of the
settlement, ImClone will pay a total of $65.0 million in cash for full and final settlement of the claims against ImClone in the matter, as well as for a royalty-free, irrevocable worldwide sublicense to technology patented under U.S. Patent
No. 4,663,281. The $65.0 million lump-sum payment ImClone has made to Repligen represents the full amount ImClone will pay to settle its litigation with MIT and Repligen. Repligen is responsible for providing MIT with its portion of
the settlement payment. 
 Importantly, pursuant to the terms of the settlement, Repligen also granted to ImClone a royalty-free, irrevocable worldwide
sublicense for the future use of other patented technology, including U.S. Patent No. 5,665,578 (the “‘578 Patent”), which is owned by Abbott Laboratories, but to which Repligen has the power to sublicense under an agreement
between Abbott Laboratories and Repligen. The ‘578 Patent is the patent upon which Abbott Laboratories sued ImClone for patent infringement earlier this year. 
 ImClone’s payment of $65.0 million to Repligen will be reflected in ImClone’s third quarter 2007 financial results. 
 “ImClone is very pleased to have reached this settlement with Repligen and MIT,” said John H. Johnson, Chief Executive Officer of ImClone. “We are happy to put this litigation behind us and move forward in our efforts to
continue to grow worldwide sales of ERBITUX ® .” 
  

 * – Confidential Treatment RequestedEmployment Agreement - Mark Peters

 Exhibit 10.1 
 EMPLOYMENT AGREEMENT 
 AGREEMENT by and between TIME WARNER TELECOM HOLDINGS INC. (the
“Company”) and Mark Peters (the “Employee”), dated as of September 28, 2007 (the “Effective Date”). 
 WHEREAS, the Company is desirous of continuing to employ the Employee in an executive capacity on the terms and conditions, and for the consideration, hereinafter set forth, and the Employee is desirous of being
employed by the Company on such terms and conditions and for such consideration. 
 NOW, THEREFORE, IT IS HEREBY AGREED AS FOLLOWS:

 1. Term. 
 (a)
Employment Period. The Company hereby agrees to continue to employ the Employee, and the Employee hereby agrees to continue to serve the Company, subject to the terms and conditions of this Agreement, for the period commencing on the
Effective Date and ending on the three year anniversary thereof (the “Employment Period”); provided that, on such three year anniversary of the Effective Date and each annual anniversary of such date thereafter (such date and
each annual anniversary thereof, the “Renewal Date”), unless previously terminated in accordance with the provisions of Section 3 hereof, the Employment Period shall be automatically extended so as to terminate one year from
such Renewal Date, unless, at least sixty (60) days prior to the Renewal Date, the Company shall give notice to the Employee that the Employment Period shall not be so extended. 
 (b) Change of Control Employment Agreement. The Employee and the Company acknowledge that they have also entered into a Change of Control
Employment Agreement (“COC Agreement”) of even date herewith. Upon the occurrence of the Effective Date as defined in the COC Agreement, this Agreement will terminate and will be superseded by the COC Agreement, except that such
termination will not relieve the Company of its obligation to pay any amount earned and payable prior to the termination of this Agreement. 
 2. Terms of Employment. (a) Position and Duties. (i) During the Employment Period, the Employee shall serve as Executive Vice President, Chief Financial Officer or in such other position as the Company shall
determine, and will perform such duties and responsibilities as may be assigned to the Employee from time to time by the Company, and shall perform his or her services at the headquarters of the Company in the Denver, Colorado area, and shall travel
for business purposes to the extent necessary or appropriate in the performance of such services. 
 (ii) During the Employment Period, and
excluding any periods of vacation and sick leave to which the Employee is entitled, the Employee agrees to devote substantially all of his or her attention and time during normal business hours to the business and affairs of the Company and, to the
extent necessary to discharge the responsibilities assigned to the Employee 

 
hereunder, to use the Employee’s reasonable best efforts to perform faithfully and efficiently such responsibilities. During the Employment Period, it
shall not be a violation of this Agreement for the Employee to serve on corporate, civic or charitable boards or committees, deliver lectures, fulfill speaking engagements or teach at educational institutions and manage personal investments, so long
as such activities do not significantly interfere with the performance of the Employee’s responsibilities as an employee of the Company in accordance with this Agreement and the Employee complies with applicable provisions of the Company’s
Code of Conduct and Code of Ethics. 
 (b) Compensation (i) Base Salary. During the Employment Period, the Employee shall
receive an annual base salary (“Annual Base Salary”) of $350,000. The Employee’s Annual Base Salary shall be reviewed at least annually by the Compensation Committee of the Board (the “Compensation Committee”)
pursuant to its normal performance review policies for senior executives. Any increase in Annual Base Salary shall not serve to limit or reduce any other obligation to the Employee under this Agreement. The Annual Base Salary shall not be reduced
and the term “Annual Base Salary” as utilized in this Agreement shall refer to the Annual Base Salary as increased from time to time. 
 (ii) Annual Bonus. In addition to the Annual Base Salary, the Employee shall be eligible to be awarded, for each fiscal year of the Company or portion of a fiscal year ending during the Employment Period, an annual bonus (the
“Annual Bonus”) pursuant to the terms of the Company’s Annual Incentive Plan, as in effect from time to time, based on a target percentage of the Annual Base Salary paid to the Employee during such fiscal year of 75% (the
“Target Bonus”). The Employee acknowledges that his or her actual annual bonus will be at the sole discretion of the Compensation Committee and may vary and range from 0% to 150% of the target amount, depending on actual performance
of the Company and the Employee. “Annual Bonus” for any given fiscal year shall mean the amount, if any, of annual bonus earned by the Employee with respect to the applicable fiscal year of the Company, including amounts deferred.

 (iii) Other Benefits. During the Employment Period: (A) the Employee shall be entitled to participate in incentive, savings
and retirement plans, practices, policies and programs of the Company to the same extent as provided generally to similarly situated executives of the Company; and (B) the Employee and/or the Employee’s family, as the case may be, shall be
eligible for participation in, and shall receive benefits under, welfare benefit plans, practices, policies and programs provided by the Company to the same extent as provided generally to similarly situated executives of the Company. The Company
reserves the right to amend or cancel any such plan, practice, policy or program in its sole discretion, subject to the terms of such plan, practice, policy or program and applicable law. 
 (iv) Expenses. During the Employment Period, the Employee shall be entitled to receive prompt reimbursement for all reasonable business expenses
incurred by the Employee in accordance with the Company’s policies. 
 3. Termination of Employment. (a) Death or
Disability. The Employee’s employment shall terminate automatically upon the Employee’s death during the Employment Period. If the Company determines in good faith that the Disability (as defined below) of the Employee has occurred
during the Employment Period, it may provide the Employee with 

  

 2 

 
written notice in accordance with Section 9(b) of this Agreement of its intention to terminate the Employee’s employment. In such event, the
Employee’s employment with the Company shall terminate effective on the 30th day after receipt of such notice by the Employee (the “Disability Effective Date”), provided that, within the thirty (30) days after such
receipt, the Employee shall not have returned to full-time performance of the Employee’s duties. For purposes of this Agreement, “Disability” shall mean the absence of the Employee from the Employee’s duties with the
Company on a full-time basis for one hundred and eighty (180) consecutive days or one hundred and eighty (180) days within any twelve month period as a result of incapacity due to mental or physical illness. 
 (b) Cause. The Company may terminate the Employee’s employment during the Employment Period either with or without Cause. For purposes of
this Agreement, “Cause” shall mean: 
 (i) being convicted of, or pleading guilty or nolo contendere
to, a charge of commission of a felony or a misdemeanor involving moral turpitude; 
 (ii) engaging in any theft,
misappropriation, embezzlement or similar financial fraud or reckless or willful destruction of the Company’s property, or willful or reckless violation of the Company’s insider trading policy; 
 (iii) the willful and continued failure of the Employee to perform substantially the Employee’s duties (as contemplated by
Section 2(a)) with the Company or its affiliated companies (other than any such failure resulting from incapacity due to physical or mental illness), after a written demand for substantial performance is delivered to the Employee by the Board
or the Chief Executive Officer of the Company that specifically identifies the manner in which the Board or the Chief Executive Officer of the Company believes that the Employee has not substantially performed the Employee’s duties; 

(iv) the willful or reckless engaging by the Employee in illegal conduct or gross misconduct that is materially injurious to the
Company’s business, financial condition or reputation; 
 (v) any willful or reckless breach of a statutory or common law
duty of loyalty to the Company that is materially injurious to the Company’s business, financial condition or reputation; 
 (vi) any willful and material violation of the Company’s Code of Conduct; or 
 (vii) any material breach of the
Employee’s obligations under this Agreement, including Section 7. 
 No act, or failure to act, shall be considered “willful” if it is
done, or omitted to be done, based upon authority (A) given pursuant to a resolution duly adopted by the Board, (B) upon the instructions of the Chief Executive Officer of the Company or (C) based upon the advice of counsel for the
Company. With respect to the conduct described in Sections 3(b)(ii) through 

  

 3 

 
3(b)(vii) above, the Company shall provide the Employee with written notice setting forth the details of any claimed breach and in the case of the conduct
described in Section 3(b)(iii) above, the Employee shall have a reasonable period of time (not less than thirty (30) days) to cure such claimed breach. 
 (c) Notice of Termination. Any termination by the Company for Cause shall be communicated by Notice of Termination (as defined below) to the other party hereto given in accordance with Section 9(b) of this
Agreement. For purposes of this Agreement, a “Notice of Termination” shall mean a written notice that (i) indicates the termination provision in this Agreement relied upon and (ii) specifies the termination date (which
date shall be not more than thirty (30) days after the giving of such notice) if the Date of Termination (as defined below) is other than the date of receipt of such notice. The failure by the Employee or the Company to set forth in the Notice
of Termination any fact or circumstance that contributes to a showing of Cause shall not waive any right of the Employee or the Company, respectively, hereunder or preclude the Employee or the Company, respectively, from asserting such fact or
circumstance in enforcing the Employee’s or the Company’s rights hereunder. 
 (d) Date of Termination. “Date of
Termination” shall mean (i) if the Employee’s employment is terminated by the Company for Cause, the date of receipt of the Notice of Termination or any later date specified therein (which date shall not be more than thirty
(30) days after the giving of such notice), as the case may be, (ii) if the Employee’s employment is terminated by the Company other than for Cause, death or Disability, the Date of Termination shall be the date on which the Company
notifies the Employee of such termination, or such later date specified by the Company, (iii) if the Employee’s employment is terminated by reason of death or Disability, the Date of Termination shall be the date of death of the Employee
or the Disability Effective Date, as the case may be, and (iv) if the Employee’s employment is terminated by the Employee for any reason, the date on which the Employee notifies the Company of such termination, or such later date as is
mutually agreed by the Company and the Employee. 
 4. Obligations of the Company upon Termination. (a) Other Than for Cause,
Death or Disability. If, during the Employment Period, the Company shall terminate the Employee’s employment other than for Cause, death or Disability: 
 (i) the Company shall pay to the Employee the aggregate of the following amounts in a lump sum in cash within thirty (30) days after
the Date of Termination, or with respect to the amounts set forth in Sections 4(a)(i)(B) and 4(a)(i)(C), if later, within eight (8) days after the Employee’s execution and delivery (without revocation) of a “Waiver and Release”
in substantially the form attached hereto as Exhibit A (the “Release”), which Release must be delivered (and not revoked) not later than 21 days after the Date of Termination (or such longer period of time permitted by the
Company, but in no event later than the latest business day that is not more than two months after the end of the calendar year in which the Date of Termination occurs) (the “Release Deadline”): 
 (A) the sum of (1) the Employee’s Annual Base Salary and any accrued vacation pay through the Date of Termination, (2) the
Employee’s 

  

 4 

 
Annual Bonus for the fiscal year immediately preceding the fiscal year in which the Date of Termination occurs (other than any portion of such Annual Bonus
that was previously deferred) if such bonus has not been paid as of the Date of Termination, and (3) the Employee’s business expenses that have not been reimbursed by the Company as of the Date of Termination that were incurred by the
Employee prior to the Date of Termination in accordance with the applicable Company policy, in the case of each of clauses (1) through (3), to the extent not theretofore paid (the sum of the amounts described in clauses (1) through
(3) shall be hereinafter referred to as the “Accrued Obligations”); and 
 (B) subject to the
Employee’s delivery (and non-revocation) of the Release not later than the Release Deadline, an amount equal to 1.5 times the sum of (1) the Employee’s Annual Base Salary and (2) the Target Bonus; and 
 (C) subject to the Employee’s delivery (and non-revocation) of the Release not later than the Release Deadline, an amount equal to
eighteen (18) months of premiums based on the premium rate charged by the Company as in effect on the Date of Termination for the health care continuation coverage mandated by the Consolidated Omnibus Budget Reconciliation Act for the type of
coverage for which the Employee is enrolled as of immediately prior to the Date of Termination less any employee contribution amount that the Employee would have otherwise paid if the Employee were actually employed by the Company or any of its
affiliated companies during the eighteen (18) month period immediately following the Date of Termination (based on the employee contribution rates as in effect on the Date of Termination); 
 (ii) the Company shall, at its sole expense as incurred, provide the Employee with outplacement services, the scope and provider of which
shall be selected by the Employee in the Employee’s sole discretion, provided that the cost of such outplacement shall not exceed $25,000; and provided, further, that such outplacement benefits shall end not later
than one year following the Date of Termination; 
 (iii) to the extent not theretofore paid or provided, the Company shall
timely pay or provide to the Employee any other amounts or benefits required to be paid or provided or that the Employee is eligible to receive under any plan, program, policy or practice or contract or agreement of the Company and its affiliated
companies through the Date of Termination (such other amounts and benefits shall be hereinafter referred to as the “Other Benefits”). 
 Notwithstanding the foregoing provisions of Section 4(a)(i), in the event that the Employee is a “specified employee” (within the meaning of Section 409A of the Code and with such classification to be determined in
accordance with the methodology established by the applicable employer) (a “Specified Employee”) and if any payment that the Employee becomes entitled to under this Agreement is considered deferred compensation within the meaning of
Section 409A of the Code, amounts (other than the Accrued Obligations) that would otherwise be payable under Section 4(a)(i) during the six-month period immediately following the Date of 

  

 5 

 
Termination shall instead be paid, with interest on any delayed payment at the applicable federal rate provided for in Section 7872(f)(2)(A) of the Code
(“Interest”), on the first business day after the date that is six months following the Employee’s “separation from service” within the meaning of Section 409A of the Code (the “409A Payment
Date”). 
 (b) Death. If the Employee’s employment is terminated by reason of the Employee’s death during the
Employment Period, this Agreement shall terminate without further obligations to the Employee’s legal representatives under this Agreement, other than (i) payment of Accrued Obligations, (ii) the timely payment or provision of Other
Benefits, (iii) an amount equal the product of (x) the Target Bonus and (y) a fraction, the numerator of which is the number of days in the fiscal year in which the Date of Termination occurs through the Date of Termination, and the
denominator of which is 365 (the “Pro-rata Bonus”), and (iv) an amount equal to the Employee’s Annual Base Salary that would have otherwise been payable during the period commencing on the Date of Termination and ending on
the date thirty (30) days following the Date of Termination (the “Supplemental Salary Payment”). Accrued Obligations, the Pro-rata Bonus and the Supplemental Salary Payment shall be paid to the Employee’s estate or
beneficiary, as applicable, in a lump sum in cash within thirty (30) days of the Date of Termination. With respect to the provision of Other Benefits, the term “Other Benefits” as utilized in this Section 4(b) shall include death
benefits as in effect on the date of the Employee’s death with respect to similarly situated executives of the Company and its affiliated companies and their beneficiaries. 
 (c) Disability. If the Employee’s employment is terminated by reason of the Employee’s Disability during the Employment Period, the
Company shall provide the Employee with (i) the Accrued Obligations, (ii) a lump sum cash payment equal to (x) 75% of the amount equal to (A) the sum of the Employee’s Annual Base Salary and Target Bonus, multiplied by
(B) 1.5, less (y) the amount of any disability benefits payable to the Employee under any disability plan, policy or program covering the Employee (the “Disability Lump Sum”) and (iii) the timely payment or delivery
of the Other Benefits in accordance with the terms of the underlying plans or agreements, and shall have no other severance obligations under this Agreement. The Accrued Obligations and the Disability Lump Sum shall be paid to the Employee in a lump
sum in cash within thirty (30) days of the Date of Termination; provided, that in the event that the Employee is a Specified Employee and if any payment that the Employee becomes entitled to under this Agreement is considered deferred
compensation within the meaning of Section 409A of the Code, the Disability Lump Sum shall instead be paid, with Interest, to the Employee on the 409A Payment Date. 
 (d) Cause; By the Employee. If the Employee’s employment shall be terminated for Cause or the Employee’s employment shall be terminated by the Employee for any reason during the Employment Period,
this Agreement shall terminate without further obligations to the Employee other than the obligation to pay to the Employee (i) the Accrued Obligations through the Date of Termination and (ii) Other Benefits, in each case to the extent
theretofore unpaid. Accrued Obligations shall be paid to the Employee in a lump sum in cash within thirty (30) days of the Date of Termination. 
 5. Non-exclusivity of Rights. Except as specifically provided, nothing in this Agreement shall prevent or limit the Employee’s continuing or future participation in any plan, 

  

 6 

 
program, policy or practice provided by the Company or any of its affiliated companies and for which the Employee qualifies pursuant to its terms, nor shall
anything herein limit or otherwise affect such rights as the Employee may have under any contract or agreement with the Company or any of its affiliated companies. Amounts that are vested benefits or that the Employee is otherwise entitled to
receive pursuant to the terms of any plan, program, policy or practice of or any contract or agreement with the Company or any of its affiliated companies at or subsequent to the Date of Termination shall be payable in accordance with such plan,
program, policy or practice or contract or agreement except as explicitly modified by this Agreement. 
 6. No Mitigation; Legal Fees. In no event shall the Employee be obligated to seek other employment or take any other action by way of mitigation of the amounts payable to the Employee under any of the
provisions of this Agreement and such amounts shall not be reduced, regardless of whether the Employee obtains other employment. In the event that the Employee prevails on substantially all material issues in any contest by the Company, the Employee
or others of the validity or enforceability of, or liability under, any provision of this Agreement or any guarantee of performance thereof (including as a result of any contest by the Employee about the amount of any payment pursuant to this
Agreement) (each, a “Contest”), the Company agrees to pay, to the full extent permitted by law, all legal fees and expenses that the Employee may reasonably incur as a result of any Contest, plus, in each case, Interest,
provided, that the Employee shall have submitted an invoice for such fees and expenses not later than 30 days after the final resolution of such Contest and the Company shall make such payment not later than 2 1
/2 months after the end of the calendar year in which such Contest is finally resolved. 
 7. Restrictive Covenants. (a) Confidential Information. The Employee shall hold in a fiduciary capacity for the benefit of the Company
all secret or confidential information, knowledge or data relating to the Company or any of its affiliated companies, and their respective businesses, that shall have been obtained by the Employee during the Employee’s employment by the Company
or any of its affiliated companies and that shall not be or become public knowledge (other than by acts by the Employee or representatives of the Employee in violation of this Agreement). After termination of the Employee’s employment with the
Company, the Employee shall not, without the prior written consent of the Company or as may otherwise be required by law or legal process, communicate or divulge any such information, knowledge or data to anyone other than the Company and those
designated by it. 
 (b) Non-competition. During the period commencing on the Effective Date and ending on the 18-month anniversary of
the Date of Termination (the “Covenant Period”), the Employee shall not, directly or indirectly or through another, be or become an officer, director, partner or employee of or consultant to or act in any managerial capacity with or own
any equity interest in any Competitive Business Entity (as defined below); provided, however, that ownership of less than one percent (1%) of the outstanding equity securities of any entity listed on any national securities
exchange or traded on the National Association of Securities Dealers Automated Quotation System shall not be prohibited hereby. A “Competitive Business Entity” is any Incumbent Local Exchange Carrier (as defined in the
Telecommunications Act of 1996), emerging telecommunications provider or cable television or communication company that competes with the Company in the provision of voice, data , Internet or other services to customers in any state of the United
States in which, as of the Date of Termination, the Company 

  

 7 

 
or its controlled affiliates engages or has publicly announced definitive plans to engage, in the ownership, operation or management of such a business.

 (c) Non-solicitation of Employees. During the Covenant Period, the Employee shall not, directly or indirectly, (i) induce or
attempt to induce any employee of the Company to leave the employ of the Company or in any way interfere with the relationship between the Company, on the one hand, and any employee thereof, on the other hand, (ii) hire any person who was an
employee of the Company until six (6) months after such individual’s employment relationship with the Company has been terminated or (iii) induce or attempt to induce any customer, supplier, licensee or other business relation of the
Company to cease doing business with the Company, or in any way interfere with the relationship between any such customer, supplier, licensee or business relation, on the one hand, and the Company, on the other hand; provided that
solicitations incidental to general advertising or other general solicitations in the ordinary course not specifically targeted at such persons and employment of any person not otherwise solicited in violation hereof shall not be considered a
violation of this Section 7(c). 
 (d) Prior Notice Required. The Employee hereby agrees that, prior to accepting employment with
any other person or entity during the Covenant Period, the Employee will provide such prospective employer with written notice of the provisions of this Agreement, with a copy of such notice delivered simultaneously to the General Counsel of the
Company. 
 (e) Documents; Conduct. The Employee hereby expressly covenants and agrees that: 
 (i) following termination of the Employee’s employment with the Company for any reason or at any time upon the Company’s
request, the Employee will promptly return to the Company all property of the Company in his or her possession or control (whether maintained at his or her office, home or elsewhere), including, without limitation, all copies of all management
studies, business or strategic plans, budgets, notebooks and other printed, typed or written materials, documents, diaries, calendars and data of or relating to the Company or its personnel or affairs; and 
 (ii) the Employee will not at any time publicly denigrate, ridicule or intentionally criticize the Company or any of its products,
properties, employees, officers or directors, including, without limitation, by way of news interviews, or the expression of personal views, opinions or judgments to the news media; provided, however, nothing in this
Section 7(e)(ii) shall prevent the Employee from making any truthful statement to the extent (A) necessary with respect to any Contest involving this Agreement or (B) required by law, subpoena or by any court, arbitrator, mediator or
administrative or legislative body (including any committee thereof) with jurisdiction to order such person to disclose or make accessible such information. 
 (f) Employee Covenants Generally. 
 (i) The Employee’s covenants as set forth in
this Section 7 are from time to time referred to herein as the “Employee Covenants.” If any of the Employee Covenants is finally held to be invalid, illegal or unenforceable (whether in whole or in part), such Employee Covenant shall
be deemed modified to the extent, but only to the extent, of 

  

 8 

 
such invalidity, illegality or unenforceability and the remaining Employee Covenants shall not be affected thereby; provided, however, that if any of the
Employee Covenants is finally held to be invalid, illegal or unenforceable because it exceeds the maximum scope determined to be acceptable to permit such provision to be enforceable, such Employee Covenant will be deemed to be modified to the
minimum extent necessary to modify such scope in order to make such provision enforceable hereunder. 
 (ii) The Employee
understands that the foregoing restrictions may limit his or her ability to earn a livelihood in a business similar to the business of the Company and its controlled affiliates, but the Employee nevertheless believes that he or she has received and
will receive sufficient consideration and other benefits as an employee of the Company and as otherwise provided hereunder to clearly justify such restrictions which, in any event (given his or her education, skills and ability), the Employee does
not believe would prevent him or her from otherwise earning a living. The Employee has carefully considered the nature and extent of the restrictions place upon him or her by this Section 7, and hereby acknowledges and agrees that the same are
reasonable in time and territory and do not confer a benefit upon the Company disproportionate to the detriment of the Employee. 
 (g)
Enforcement. Because the Employee’s services are unique and because the Employee has access to confidential information, the parties hereto agree that money damages would be an inadequate remedy for any breach of this Section 7.
Therefore, in the event of a breach or threatened breach of this Section 7, the Company or its respective successors or assigns may, in addition to other rights and remedies existing in their favor at law or in equity, apply to any court of
competent jurisdiction for specific performance and/or injunction relief in order to enforce, or prevent any violations of, the provision hereof (without posting a bond or other security) or require the Employee to account for and pay over to the
Company all compensation, profits, moneys, accruals or other benefits derived from or received as a result of any transactions constituting a breach of the covenants contained herein, if and when final judgment of a court of competent jurisdiction
is so entered against the Employee. 
 (h) Interpretation. For purposes of this Section 7, references to “the Company”
shall mean the Company as hereinbefore defined and any of its controlled affiliated companies. 
 8. Successors. (a) This
Agreement is personal to the Employee and without the prior written consent of the Company shall not be assignable by the Employee otherwise than by will or the laws of descent and distribution. This Agreement shall inure to the benefit of and be
enforceable by the Employee’s legal representatives. 
 (b) This Agreement shall inure to the benefit of and be binding upon the Company
and its successors and assigns. 
 (c) The Company will require any successor (whether direct or indirect, by purchase, merger, consolidation
or otherwise) to all or substantially all of the business and/or assets of the Company to assume expressly and agree to perform this Agreement in the same manner and to the same extent that the Company would be required to perform it if no such

  

 9 

 
succession had taken place. As used in this Agreement, “Company” shall mean the Company as hereinbefore defined and any successor to its business
and/or assets as aforesaid that assumes and agrees to perform this Agreement by operation of law or otherwise. As used in this Agreement, the term “affiliated companies” shall include any company controlled by, controlling or under common
control with the Company. 
 9. Miscellaneous. (a) This Agreement shall be governed by and construed in accordance with the laws
of the State of Delaware, without reference to principles of conflict of laws. The captions of this Agreement are not part of the provisions hereof and shall have no force or effect. This Agreement may not be amended or modified otherwise than by a
written agreement executed by the parties hereto or their respective successors and legal representatives. 
 (b) All notices and other
communications hereunder shall be in writing and shall be given by hand delivery to the other party or by registered or certified mail, return receipt requested, postage prepaid, addressed as follows: 
  

			
	If to the Employee:	  	 At the most recent address
 on file at the Company.

		
	If to the Company:	  	 Time Warner Telecom, Inc.
 10475 Park Meadows Drive

 Littleton, Colorado 80124
 Attention: General
Counsel
 Facsimile: (303) 566-1011

  
 or to such other address as either party
shall have furnished to the other in writing in accordance herewith. Notice and communications shall be effective when actually received by the addressee. 
 (c) The invalidity or unenforceability of any provision of this Agreement shall not affect the validity or enforceability of any other provision of this Agreement. 
 (d) The Company may withhold from any amounts payable under this Agreement such federal, state, local or foreign taxes as shall be required to be
withheld pursuant to any applicable law or regulation. 
 (e) The Employee’s or the Company’s failure to insist upon strict
compliance with any provision of this Agreement or the failure to assert any right the Employee or the Company may have hereunder shall not be deemed to be a waiver of such provision or right or any other provision or right of this Agreement.

 (f) Any provision of this Agreement that by its terms continues after the expiration of the Employment Period or the termination of the
Employee’s employment shall survive in accordance with its terms. 
 (g) Within the time period permitted by the applicable Treasury
Regulations, the Company may, in consultation with the Employee, modify the Agreement in order to cause the provisions of the Agreement to comply with the requirements of Section 409A of the Code, 

  

 10 

 
so as to avoid the imposition of taxes and penalties on the Employee pursuant to Section 409A of the Code, while not substantially reducing the
aggregate value to the Employee of the payments and benefits to, or otherwise adversely affecting the rights of, the Employee under this Agreement. 
 (h) This Agreement supersedes and replaces in whole the Employment Agreement dated April 1, 2005 between the Company and Employee, and that Agreement shall be of no further force and effect. 
 IN WITNESS WHEREOF, the Employee has hereunto set the Employee’s hand and, pursuant to the authorization from its Board, the Company has caused
these presents to be executed in its name on its behalf, all as of the day and year first above written. 
  

			
	MARK PETERS
	
	/s/ Mark Peters
	
	TIME WARNER TELECOM HOLDINGS INC.
		
	By:	 	/s/ Larissa Herda
		 	Larissa Herda
		 	Chairman, CEO and President

  

 11

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00132-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00132-of-00352.parquet"}]]